SPROUTY PROTEIN AND CODING SEQUENCE

Abstract: A new class of mammalian sprouty proteins is disclosed. The proteins are characterized by an amino acid sequence whose cysteine-rich region has at least 40 % sequence identity with SEQ ID NO:17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO:8. Also disclosed are (i) a pharmaceutical preparation containing a sprouty protein, (ii) a DNA sequence encoding the protein, (iii) vector and gene therapy compositions containing the DNA coding sequence, and (iv) methods of detecting a condition characterized by, or risk factor associated with, abnormal levels of active mammalian sprouty protein in a mammalian subject.

Description: SPROUTY PROTEIN AND CODING SEQUENCE This application claims the benefit of U.S. Provisional Application No. 60/030,232, filed November 7, 1996. Field of the Invention The present invention relates to modulators of the FGF signalling pathway, particularly to modulators of FGF-mediated endothelial tube branching, e.g., capillary branching (angiogenesis) and tracheal branching, and methods of use thereof. References Ausubel, F.M., et al, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. John Wiley and Sons, Inc., Media PA (1988). Artavanis, T.S., et al, Science 268:225-232 (1995). Beck-Sickinger, and Jung, Biopolymers 37: 123-142 (1995). Bellen, H., et al, Genes Dev. 3: 1288-1300 (1989). Betageri, G.V. , et al, "Targeting of Liposomes" in LiPOSQME DRUG DELIVERY SYSTEMS (Technomic Publishing Co., Inc., Lancaster, PA, pp. 89-108 (1993). Bier, E., et al, Genes Dev. 3: 1273-1287 (1989). Brand, A.H., and Perrimon, N. , Development 118:401-415.(1993). Brunner, D., et al, Nature 370:386-389 (1994). Edgar, B.A., et al , Development 120:3131-43 (1994). Gabay, L. , et al , Development 122:3355-3362 (1996). Glazer and Shilo, Proc. Natl. Acad Sci. 87:3851-3855 (1990). Goldberg, J., et al , Eur. J. Biochem. 218:597-601 (1993). Guillemin, K., et al, Development 122: 1353-1362 (1996). Hacohen, N., Ph.D. Thesis, Leland Stanford Junior University, Stanford, CA (1997). Harlow, E. , et al, ANTIBODIES: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988). Klaes, A., et al, Cell 78: 149-160 (1994). Kramer, S., et al, Development 121 : 1361-1372 (1995). Lai, Z.-C, and Rubin, G.M. , Cell 70:609-620 (1992). Lee, et al, Nucleic Acid Research 21:3761-3766 (1993). Lennon, G., et al , Genomics 33:151-2 (1996). Lin, D.M. , and Goodman, C.S., Neuron L3:507-523 (1994). Lindsley, D.L., and Zimm, G.G., THE GENOME OF DROSOPHILA MELANOGASTER. Academic Press, San Diego, CA (1992). Lis, J.T., et al , Cell 39:403-410 (1983). Lundegren, U., et al, Science 241: 1077 (1988). Moore, G.J. , Trends in Pharmacological Sciences 15: 124-129 (1994). Mullis, K.B., et al , U.S. Patent No. 4,683,195, issued July 28, 1987. Mullis, K.B., U.S. Patent No. 4,683,202, issued July 28, 1987. Nagashima, M. , et al, J. Biol Chem. 268:2888-2892 (1993). O'Neill, E.M., et al, Cell 78: 137-147 (1994). O'Reilly, M.S., et al, Cell 79:315-328 (1994). Perrimon, N., et al, Dev. Genet. 12:238-52 (1991). Rebay, I., and Rubin, G.M. , Cell 81:857-866 (1995). Robertson, H.M. , et al , Genetics 118:461-470 (1988). Saiki, R.K., et al, Science 230: 1350 (1985). Samakovlis, C, et al, Development 122: 1395-1407 (1996). Sambrook, J., et al , MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989). Scholz, H. , et al, Genetics 135:455-468 (1993). Sutherland, D.C., et al, Cell 87: 1091-1101 (1996). Tautz, D. , and Pfeifle, C , Chromosoma 98:81-85 (1989). White, K., et al, Science 264:677-683 (1994). Whitely, N.M., et al, U.S. Patent 4,883,750 (1989). Winn-Deen, E. , et al , Clin. Chem. 37:(1522) (1991). Wohlwill, A.D. , and Bonner, J.J. , Genetics 128:763-775 (1991). Wu, D.Y., et al , Genomics 4:560 (1989). Xu, T., and Rubin, G.M., Development 117:1223-1237 (1993). Zinn, K., et al , Cell 53:577-87 (1988). Background of the Invention Normal capillaries are composed of endothelial cells and pericytes and serve to transport blood to all body tissues. Neovascularization, or angiogenesis, is the growth and development of new capillaries from existing vessels. Angiogenesis is essential for the initial formation of the vascular system as well as for reproduction and wound healing. There are, however, conditions characterized by unregulated persistent neovascularization, including a variety of tumor cancers, diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis and psoriasis. It is therefore desirable to understand the molecular basis of angiogenesis, as a basis for designing therapeutic strategies for treating conditions, such as cancer, characterized by unregulated, persistent neovascularization, or conditions, such as wound healing where increased vascularization is needed. Summary of the Invention The invention includes, in one aspect, an isolated recombinant sprouty polypeptide comprising (i) a protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity, and preferably at least 50% sequence identity, with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO: 8, or (ii) a peptide derived therefrom, and having at least 10 amino acids. Exemplary proteins include the human sprouty 2 protein having a sequence substantially identical to SEQ ID NO: 8, the human sprouty 1 protein containing a sequence substantially identical to SEQ ID NO:6, and the human sprouty 3 protein containing a sequence substantially identical to SEQ ID NO: 11. The protein may be used, for example, in treating a solid tumor in a patient, by administering to the patient an amount of the protein effective to inhibit tumor growth. In this treatment method, the protein may be encapsulated in liposomes having an average size less than about 150 nm, and a surface coating of polyethyleneglycol. In another aspect, the invention includes an isolated DNA fragment that encodes a sprouty polypeptide comprising (i) a protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity, and preferably at least 50% sequence identity, with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO: 8, or (ii) a peptide derived therefrom, and having at least 10 amino acids. Exemplary sequences include those that encode (i) a human sprouty 2 protein having a sequence substantially identical to SEQ ID NO: 8, such as the DNA sequence identified by SEQ ID. NO:7, (ii) a human sprouty 1 protein containing a sequence substantially identical to SEQ ID NO: 6, such as the DNA sequence containing a region identified by SEQ ID. NO:5, and (iii) a human sprouty 3 protein containing a sequence substantially identical to SEQ ID NO: 11, such as the DNA sequence containing a region identified by SEQ ID. NO: 10. In a related aspect, the invention includes a recombinant expression vector, comprising the DNA coding sequence above, and a regulatory sequence operable linked to the fragment and capable of promoting expression of the protein in a selected host. The vector may be complexed with a polycation to form a condensed particle having a size less than about 150 nm, for use transfecting cells, to increase secretion of the sprouty protein from the cells. The complex may further include a targeting moiety capable of binding specifically to tumor cell surfaces. Also disclosed is a mammalian cell transformed with the vector. In still another aspect, the invention includes a method of detecting a condition characterized by, or risk factor associated with, abnormal levels of active mammalian sprouty protein in a mammalian subject. The method includes obtaining genomic DNA or cDNA from the subject, and examining the DNA or cDNA for the presence or absence of mutations relative to the human sprouty genes selected from the group consisting of genes identified by SEQ ID NO: 5, SEQ ID NO:7, and SEQ ID NO: l l . The invention also includes a method of detecting a condition characterized by, or risk factor associated with, abnormal levels of active mammalian sprouty protein in a mammalian subject. The method includes obtaining fluid from a tissue or organ in the subject, reacting the fluid with an antibody against a human sprouty protein of the type described above, and to form a protein-antibody complex, and identifying the presence of such complex. These and other objects and features of the invention will become more fully apparent when the following detailed description is read in conjunction with the accompanying drawings. Brief Description of the Figures Figs. 1A, IB and 1C are schematic diagrams of unicellular branches in the developing Drosophila tracheal system. The fifth tracheal unit is shown at stage 12 (Fig. 1A), stage 16 (Fig. IB), and third instar larval (Fig. 1C). Figs. 2A-2H are photomicrographs showing ectopic dorsal (DB) and ganglionic (GB) branches in wild type ( + ) and Spry 5 mutant embryos. Figs. 2A, 2C, 2E and 2G show whole embryos; Figs. 2B, 2D, 2F and 2H show close-ups. Figs. 3A-3L show the distribution of cells and expression of branching markers in the wild type ( + ) and Spry 5 mutant tracheal systems. Figs. 3A, 3B, 3E and 3F are photomicrographs of dorsal branches; Figs. 3C and 3D are tracings of ganglionic branches; Figs 3K and 3L are photomicrographs of wild type (Fig. 3K) and Spry 5 (Fig. 3L) larval dorsal branches. Figs. 4A, 4B and 4C are photomicrographs of mosaic clones of Spry and wild type cells distinguished by expression (Spry + ) or lack of expression of cytoplasmic 3-gal (Spry ). Figs. 5A-5D show the Spry genomic locus (Fig. 5A), Spry expression pattern (Fig. 5B), Spry DNA and amino acid sequences (Fig. 5C), and Spry sequence alignments (Fig. 5D). Figs. 6A, 6B and 6C are photomicrographs of stage 14 embryos showing the subcellular localization of Spry (red) and notch (green) proteins. Figs. 7A-7H are photomicrographs showing the timecourse of Spry-lacZ (Figs . 7A- 7D, 7F and 7H) and Spry mRNA (Figs. 7E and 7G) expression in Drosophila embryos. Figs. 8A, 8B and 8C are photomicrographs showing the effects of ectopic expression of Spry protein in Drosophila embryos. Figs.. 9A-P are photomicrographs illustrating the effects of Spry mutations on the Bnl pathway in Drosophila embryos as detailed in Example 9. Figs. 9A-E show the effects of Spry mutations on expression of Spry and pnt; Figs. 9F-9K show the effects of Spry mutatations on expression of DSRF; Figs. 9L-N show the effects of Spry mutations on expression of Yan; and Figs. 90 and 9P indicate the effect of elevated levels of Spry; Figs.. 10A-F demonstrate the effect of Bnl pathway mutations on Spry expression as detailed in Example 10. Fig. 10A is a schematic representation of DB development in wild type cells expressing Bn-1; Figs. 10B-F illustrate the effect of Bnl pathway mutants on Spry expression in the developing DB, visualized by immunostaining of the Spry9143 marker; Fig. 11 presents a schematic model of a BNl-Spry regulatory circuit; and Figs.. 12A-C present Western blot results corresponding to expression of Spry proteins, drosophila Spry and human Spryl, in cell culture (Example 11), where Fig. 12A corresponds to 66kD Drosophila Spry; Fig. 12B shows hSpryl protein at 35-40kD; and Fig. 12C corresponds to the 100K rpm pellet and supernatant of homogenized cells expressing Drosophila Spry. Fig. 13 shows the aligned amino acid sequences for full-scale Drosophila Spry and human Spry 2 protein, and partial sequences for human Spry 1, human Spry 3, mouse Spry 1 and mouse Spry 4 proteins. Detailed Description of the Invention I. Definitions A polypeptide sequence or fragment is "derived" from another polypeptide sequence or fragment when it has the same sequence of amino acid residues as the corresponding region of the fragment from which it is derived. A polynucleotide sequence or fragment is "derived" from another polynucleotide sequence or fragment when it has the same sequence of nucleic acid residues as the corresponding region of the fragment from which it is derived. A first polynucleotide fragment is "selectively-hybridizable" to a second polynucleotide fragment if the first fragment or its complement can form a double-stranded polynucleotide hybrid with the second fragment under selective hybridization conditions. The first and second fragments are typically at least 15 nucleotides in length, preferably at least 18-20 nucleotides in length. Selective hybridization conditions are defined herein as hybridization at ~ 45°C in ~ 1.1M salt followed by at least one wash at 37°C in 0.3M salt. Two or more polynucleotide or polypeptide fragments have at least a given percent "sequence identity" if their nucleotide bases or amino acid residues are identical, respectively, in at least the specified percent of total base or residue position, when the two or more fragments are aligned such that they correspond to one another. "Substantially purified" refers to the at least partial purification of a polynucleotide, polypeptide, or related compound (e.g., anti-Spry antibodies) away from unrelated or contaminating components (e.g. , serum cells, proteins, and non-anti-S/?ry antibodies). Methods and procedures for the isolation or purification of compounds or components of interest are described below (e.g. , affinity purification of fusion proteins and recombinant production of Spry polypeptides). The term "Spry polynucleotide" refers to (i) an isolated DNA fragment that encodes a sprouty polypeptide comprising (a) a protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity, and preferably at least 50% sequence identity, with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO: 8, or (b) a peptide derived therefrom and having at least 10 amino acids. In the alternative, the term refers to a polynucleotide containing a region of at least 30, preferably at least 100 nucleotides in length that is selectively- hybridizable with the sequence presented herein as SEQ ID NO: l , SEQ ID NO:5, SEQ ID NO: 7 or the complement of one of the sequences. A "Spry polynucleotide" refers to a polypeptide comprising (a) a protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity, and preferably at least 50% sequence identity, with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO:8, or (b) a peptide derived therefrom and having at least 10 amino acids. II. Identification of Sprouty Alleles Causing Excessive Tracheal Branching Mutagenesis studies, detailed in Example 1, were performed to identify the gene responsible for the expression pattern of the Pantip-2 tracheal marker. The Pantip-2 tracheal marker is a P[lacZ\ insert at 63D1,2 in which the beta-galactosidase marker protein is expressed in tracheal cells as they form branches (Samakovlis, et al , 1996). The original insert (2683) was homozygous viable and showed a normal tracheal branching pattern. One hundred P-element excision alleles were generated by introduction of transposase and scored for lethality and embryonic tracheal phenotypes. Of the twelve lethal excision alleles recovered, three (sprouty A5 , sprouty * M , and sprouty ^ showed extra tracheal branches as described below and represented a single complementation group. As detailed in Example 2, Spry 5 1 Spry 5 embryos had 1.5 to 2 times as many fine branches as normal emanating from most primary branches (dorsal branch, lateral trunk anterior and lateral trunk posterior and ganglionic branch) at embryonic stage 16 and — 30% more branches than normal emanating from the visceral branch (Fig. 2, Table 1). The extra tracheal branches arose in many positions throughout the tracheal network (Fig. 2C, G) but were not distributed randomly. Rather, the extra branches were clustered around the sites where secondary and terminal branches normally form (Fig. 2B, H). The primary branching pattern was not affected in Spry mutants: all primary branches grew to their normal lengths and reached their destinations at the appropriate times in development. The other excision alleles (Spry ΛM , Spry* 55 ) showed a similar phenotype, although Spry* 55 was weaker than the others. Five EMS-induced Spry alleles (Spry 254 , Spry 211 , Spry 226 , Spry 05 - Spry 7 ), recovered in an unrelated screen for mutations that suppress a dominant eye phenotype (Kramer, et al , 1995), mapped to the same genetic interval in the 63D region and had the same tracheal phenotype as Spry* 5 (Table 1). Spry 254 was tested and failed to complement the three original Spry alleles for tracheal function and lethality. Molecular analysis of all the EMS mutants identified lesions in Spry coding sequences. All eight Spry mutations resulted in pupal lethality in trans to deficiencies in the 63D region including Df(3L) 1226, Df(3L) 1227, Df(3L) Hrl l9, Df(3L) Hr232. Spry* 5 homozygotes displayed as severe a tracheal phenotype as Spry* 5 /O (3L) 1226 and Spry^/Df (3L) Hr298, indicating that Spry* 5 is a strong loss-of-function or null allele (Table 1). A genetic mosaic analysis of Spry in the developing tracheal system was carried out as described in Example 4, below, to determine in which cells the Spry gene functions to inhibit branching. Homozygous Spry* 5 mutant clones were generated in Spry* 5 1 + animals using FLP-mediated mitotic recombination (Xu and Rubin, 1993) between the Spry* 5 chromosome and a Spry + chromosome that also carried a general tracheal lacZ marker. The Spry* 5 1 Spry* 5 mutant tracheal cells were identified by the absence of expression of the lacZ marker. Drosophila Spry (Dro Spry) cDNA was cloned as described in Example 5. The genomic structure, expression pattern and cDNA and amino acid sequences of Dro Spry are shown in Figs. 5A-5D. Fig. 5 A shows a diagram of the Dro Spry genomic locus and gene structure. Three classes of cDNAs were isolated and mapped onto the genomic contig of the region by the use of genomic Southerns, PCR and DNA sequencing. Exons are indicated by boxes; a filled-in box is an open reading frame; an unfilled box is an untranslated region. An 8kb Hindlll/BamHl genomic fragment was used to screen an embryonic Drosophila cDNA library. Eleven cDNA clones, falling into three size classes, were isolated. The assignment of classes was verified by cross-hybridization and restriction enzyme analyses as well as sequencing. Exons were mapped by hybridization of cDNA fragments to digested genomic phage DNA. Intron/exon boundaries were determined by PCR analysis of genomic DNA using primers from the cDNAs and by sequencing the relevant regions of genomic DNA. Fig. 5C shows the polynucleotide (SEQ ID N0: 1) and translated amino acid (SEQ ID NO:2) sequences of cDNA clone 12.2. Analysis of the protein sequence suggests that the Spry protein is a 63 kD membrane-bound or secreted protein containing a novel 124 residue cysteine-rich region (SEQ ID NO:4). The 124 residue region is encoded by the sequence presented herein as SEQ ID NO: 3. III. Properties of the Spry Protein A. Spr Encodes a Lateral Inhibitory Signal Lateral inhibition is a process by which a single cell within an equipotent group of cells that is singled out to adopt a particular fate inhibits its neighbors from adopting that same fate (Artavanis, et al , 1995). In the absence of lateral inhibition, either by ablating the selected cell or by inactivating components of the lateral signaling pathway, other cells within the equivalence group adopt the same fate. Data presented herein support the function of sprouty as a lateral inhibitory signal during epithelial tube branching. As shown in Figs. 2A-H, extra tracheal branches arising around the normal sites of branching develop in Spry loss-of-function mutants. The extra branches are indistinguishable by morphology or marker expression (Figs. 3A-3L) from the normal branches and arise by conversion of non-branching cells to the branching fate. Further, Spry is expressed in the branch-forming cells, and genetic mosaic analysis shows that the gene is required in these cells and acts non-autonomously to inhibit neighboring cells from branching (Figs. 4A-4C). Finally, the Spry gene encodes a protein with a putative signal peptide and a long cysteine-rich domain (Fig. 5C), and immunolocalization studies detected the protein in vesicles and at the plasma membrane (Figs. 6A-6C), indicating that Spry is a secreted or membrane-associated protein. These data demonstrate that Spry protein is the lateral inhibitory signal or an essential component of it. The role of Spry in inhibition of branching outside the tracheal system is supported by data showing that Spry is expressed in several developing Drosophila tissues in addition to the tracheal system and appears to function in inhibitory signaling pathways in at least some of these tissues. In Spry mutant embryos, extra tracheal branches sprout near the normal sites of branching. Cells that give rise to the ectopic branches are indistinguishable from normal branch-forming cells and arise by the transformation of normally non-branching cells to the branch-forming fate. Analysis of mosaic clones showed that Spry is required in the normal branch-forming cells to inhibit branch formation by surrounding cells. Spry encodes a novel membrane-associated or secreted protein, containing a 124 residue cysteine-rich domain, that inhibits the switch to the branching cell fate and helps restrict fine branching to the proper positions within the tracheal epithelium. B. Spry Limits the Range of Bnl Signalling Further experiments carried out in support of the gene family described herein show that Spry encodes an inhibitor that limits the range of Bnl signaling in Drosophila, to thereby restrict secondary budding to apical positions closest to the FGF signaling centers (Examples 9 and 10). The branchless gene (bnl) encodes a fibroblast growth factor (FGF) homolog that plays a key role in branching events (Sutherland, et al., 1996). Bnl is required for branching and is expressed dynamically in discrete clusters of cells surrounding the tracheal sacs, at a position where a new branch will bud. The secreted growth factor activates the breathless FGF receptor (Btl), a receptor tyrosine kinase (RTK) expressed on all tracheal cells (Glazer and Shilo, 1991; Lee et al., 1996), and guides trachael cell migrations during primary branch formation. Bnl also has a secondary role in branch patterning: it induces the later programs of branching in cells near the ends of the growing primary branches and in this way contributes to the apical bias in secondary branching. This function appears to be transduced by a typical RTK signaling cascade (Lee et al., 1996; Sutherland et al., 1996; Hacohen, 1997) that culminates in the MAPK-dependent degradation of Yan, an ETS domain transcription factor (Lai and Rubin, 1992) and the induction of the downstream effector genes pointed, another ETS domain transcription factor and blistered/pruned, which encodes DSRF, the Drosophila homolog of mammalian Serum Response Factor (Guillemin, et al, 1996). To determine whether Spry+ functions by limiting the Bnl pathway or whether it prevents branching in some other way, the effect of Spry mutations on downstream effectors (pnt, Yan, DSRF gene) in the Bnl pathway was examined (Example 9). In Spry mutants, all five downstream effectors examined (pnt, Yan, DSRF, Terminal -2, -3, -4) were expressed in an expanded domain that included the pre-stalk chalk cells that later formed ectopic branches (Figs. 9B, E, G, and I). The DSRF marker was activated at the same time as in the normal branching cells (Figs. 9J, K). In Spry mutans, Yan was degraded in an expanded domain that coincided with the expanded domains of pnt and DSRF expression (Figs. 9L, M). These findings demonstrate that Spry loss of function mutations lead to enhancement of all of the known downstream effectors in this Bnl pathway. Moreover, an engineered gain of function condition in which the Spry gene product was overexpressed during embryonic stages 10-12 severely blocked the normal induction of downstream effectors and branching by Bnl (Figs. 90,P). These results reveal that Spry functions genetically as a competitive antagonist of the Bnl pathway. Additional experiments carried out in support of the invention indicate that Spry expression is induced by the Bnl signaling pathway (Example 10). IV. Sprv Polypeptides Fig. 13 shows the alignment of aligned amino acid sequences for full-scale Drosophila Spry and hSpry2 (human Spry!) protein, and partial sequences for hSpryl , hSpry3, mSpryl (mouse Spryl) and mSrpy4 proteins. The region of particular interest in this figure is the region between residue number 380 and 424, where the amino acid residue numbers refer to amino acid residue numbers for the Drosophilia protein. This region is also referred to herein as the most cysteine-rich region of Spry proteins, to distinguish it from the larger cysteine-rich region defined by regions 380-503 in the figure. In the three human Spry proteins in the figure (top three lines), the 45 amino acid sequences in the most cysteine-rich region are identified for the hSpryl, hSpryl, and hSpry3 by SEQ ID NOs: 17, 18, and 19, respectively. The three regions have 25/45 sequence identity, i.e., about 55% sequence identity. More generally, a Spry polypeptide as defined herein is a protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity, and preferably at least 50% sequence identity, with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO: 8. Spry polypeptides also encompass peptides derived from the Spry proteins and having a sequence of at least 10 amino acids. That is, the peptide contains 10 amino acids that match a lOmer sequence in a Spry protein, as defined above. Preferably, the peptide contains at least 15, preferably at least 20 contiguous amino acids from a Spry protein. Spry polypeptides may be produced recombinantly or synthetically. An example of recombinant production is described in the Materials and Methods, where a pGEX-derived plasmid (pGEX-4T-2, obtained from Pharmacia Biotech, Piscataway, NJ) was used to express Spry polypeptides for the generation of antibodies. The pGEX plasmid (Smith, et al., 1988) and its derivatives express the polypeptide sequences of a cloned insert fused in- frame with glutathione-S-transferase. Recombinant pGEX plasmids can be transformed into appropriate strains of E. coli and fusion protein production can be induced by the addition of IPTG (isopropyl-thio galactopyranoside). Solubilized recombinant fusion protein can then be purified from cell lysates of the induced cultures using glutathione agarose affinity chromatography according to standard methods (Ausubel, et al, 1988). Affinity chromatography may also be employed for isolating β-galactosidase fusion proteins (such as those produced by lambda gtl l clones). The fused protein is isolated by passing cell lysis material over a solid support having surface-bound anti-0-galactosidase antibody. Expression of drosophila Spry and human Spryl under the control of a mammalian EF-lα promoter in human 293 cells is described in Example 11. Isolated recombinant polypeptides produced as described above may be purified by standard protein purification procedures. These procedures may include differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis and affinity chromatography. In addition to recombinant methods, Spry proteins or polypeptides can be isolated from selected cells by affinity-based methods, such as by using &τλύ-Spry antibodies (described below). Further, Spry peptides may be chemically synthesized using methods known to these skilled in the art. Polypeptides of the present invention may be used in a number of ways, including the generation of antibodies. The polypeptides may be used in unmodified form, or they may be coupled to appropriate carrier molecules, such as bovine serum albumin (BSA) or Keyhole Lympet Hemocyanin (KLH) (available from, for example, Pierce, Rockford, IL). V. Spry Polynucleotides A Spry polynucleotide as defined herein is a polynucleotide coding for a Spry protein as defined above, meaning an amino acid sequence whose cysteine-rich region has at least 40% sequence identity, and preferably at least 50% sequence identity, with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO: 8, or a peptide derived from a Spry protein and having a sequence of at least 10, and preferably at least 15-20 amino acids. That is, the peptide contains 10 amino acids that match a lOmer sequence in a Spry protein, as defined above. An NCBI BLAST search of the combined databases did not detect any closely related proteins. However, a search of the expressed sequence tag (dbEST) database identified three human homologs referred to herein as hSpryl (SEQ ID NOs:5, 6) (clone 142025, IMAGE consortium clones, Lennon, et al, 1996), hSpryl (SEQ ID NOs:7,8,9) (clone 40262), and hSpry3 (SEQ ID NOs: 10,11; clone XAP128). A complete coding sequence was determined for hSpryl (40262) (SEQ ID NO: 7) and a partial sequence was determined for hSpryl from overlapping cDNAs (142025, 78383 and 727987), (SEQ ID NO:5). The hSpryl sequence predicts a 315 residue polypeptide with a mass of 35 kD. It contains a cysteine-rich domain which is highly conserved with Spry (51 % identity with 21 of the 22 Spry cysteines conserved) and two additional short stretches of similarity with Spry in the N-terminal region. hSpryl and hSpry3 also show strong conservation of the cysteine-rich domain, with 51-70% identity to other family members in the available sequences. Additional mouse ESTs found to be part of the sprouty gene family included mSpryl, SEQ ID NOs: 12, 13 (907842), mSpryl, SEQ ID NO: 14 (819774) and mSpry4, SEQ ID NOs: 15, 16 (919795). An alignment of the full hSpryl sequence and partial sequences of hSpryl and hSpry3 with the Drosophila Spry sequence is shown in Fig. 5D. Referring now to Fig. 5D, identities are highlighted in grey and dots represent gaps inserted to maximize alignment. Numbers in parentheses indicate the number of Spry residues not shown. The cysteine-rich domain and two short regions of homology with Spry are boxed. In the cysteine-rich domain, hSpryl is 51 % (56 of 109 residues), hSpryl is 51 % (64 of 124 residues), and hSpry3 is 60% (27 of 45 residues) identical to Spry, and — 57-70% identical to each other. The asterisks show the cysteines in Spry and (*) shows the one cysteine not conserved in hSpryl. These results suggest a novel conserved cysteine-rich domain plays a major functional role in the protein. Full-length clones of hSpryl and hSpryl may be isolated by one of skill in the art using guidance herein (in particular, the sequence information) in combination with known molecular biology techniques. For example, overlapping clones can be obtained by employing one of the human clones (e.g., hSprylA clone (SEQ ID NO:5) or hSprylA clone (SEQ ID NO: 7)) or fragments thereof as probes in screening random-primed or oligo (dT)- primed human cDNA libraries generated from stage-appropriate (e.g., embryonic) endothelial cells. Such libraries are available, e.g., from Clontech (Palo Alto, CA). Positive clones are isolated, sequenced, and new sequence information is used for generating probes for additional rounds of screening. Fragments from the appropriate region of a clone can be generated using, for example, polymerase chain reaction or cleavage with restriction endonucleases. These fragments can be used as radiolabelled probes in screens of libraries generated, for example, in lambda gtlO. In particular, the 5' and 3' terminal sequences of the clone inserts are useful as probes to identify additional, overlapping clones. If a full length cDNA is not isolated from a library, overlapping clones can be spliced together to generate a full length insert using well-known techniques (Ausubel, et al. , 1988; Sambrook, et al , 1989). For example, the full length sequence is analyzed with a sequence analysis program, such as "MACVECTOR" (IBI, New Haven, CT), for unique endonuclease restriction sites in regions of overlap between two inserts. The clones are digested with endonuclease(s) to isolate the insert from the vector, and an endonuclease that cuts in the overlap region. The digested inserts are isolated on a preparative gel, purified, and ligated to form an insert spanning the range of the two source inserts. VI. Diagnostic Applications The Spry proteins and coding sequences have utility in detecting (i) the presence or absence of mutations in a Spry gene, and (ii) the level of Spry proteins present in a given tissue or organ, including a solid tumor present as a primary or secondary tumor in a given tissue or organ. A. Presence or Absence of a Spry Gene Mutation It is of interest to detect mutations within one or more Spry genes to determine (i) an individual's genetic predisposition to pathogenic conditions, such as cancer, affected by branching mechanisms, or (ii) the possible role of a defected Spry gene in an existing condition, such as cancer, as a basis for therapy. In the former, case, somatic cells from any convenient tissue source, e.g., blood cells, may be employed as the source of genomic DNA. In the latter case, cDNA is preferably obtained from pathogenic cells, e.g. , tumor cells, to allow for evaluation of the level of Spry gene transcript as well as presence or absence of a mutation in the coding region of the gene. Methods of obtaining genomic DNA and cDNA are well known (see, for example, Sambrook, et al, 1989) The presence or absence of mutations can be determined by one of a variety of available techniques. In one method, genomic DNA or cDNA is amplified by PCR, using selected primers from the known coding sequences (Mullis, 1987; Mullis, et al, 1987; Saiki). Typically, the primers are selected to amplify the full-length coding sequence, or as large a fragment of coding sequence as is known. The amplified fragments are then fractionated and sequenced by standard methods, such as dideoxy termination sequencing or sequencing by hybridization. Alternatively, Southern blotting for identifying fragments in a restriction-enzyme DNA digest which contain a given probe sequence, and for analyzing restriction-fragment length polymorphisms (RFLPs). This technique can detect point mutations at restriction cutting sites, and deletion, addition or rearrangement mutations with a RFLP band. It will be appreciated that as mutations present in the population as a whole become known and catalogued, methods for quickly detecting one of a number of known mutations can be employed. For example, as many as 200 different mutations have been associated with cystic fibrosis. Methods of identifying known target sequences by probe ligation methods have been reported (Wu, et al, 1989; Whitely, et al, 1989; Lundegren, et al, 1988; Winn-Deen, et al, 1991). In one approach, known as oligonucleotide ligation assay (OLA), two probes or probe elements which span a target region of interest are hybridized with the target region. Where the probe elements match (basepair with) adjacent target bases at the confronting ends of the probe elements, the two elements can be joined by ligation, e.g. , by treatment with ligase. The ligated probe element is then assayed, evidencing the presence of the target sequence. In a modification of this approach, the ligated probe elements act as a template for a pair of complementary probe elements. With continued cycles of denaturation, reannealing and ligation in the presence of the two complementary pairs of probe elements, the target sequence is amplified geometrically, allowing very small amounts of target sequence to be detected and/or amplified. This approach is also referred to as Ligase Chain Reaction (LCR). The level of Spry gene transcript in a given tissue, e.g. , may be determined, for example, by quantitative PCR methods, in which a mixture of test cDNA and a mixture of normal (control) DNA are amplified in parallel, and then compared for relative amounts, e.g. , by fractionation on a gel and quantitation of radiolabeled DNA in amplified and control and test labeled DNA. B. Measuring levels of Spry Protein Measuring the presence or absence of Spry protein, or the level of Spry protein in a given sample, e.g. , a tumor sample, is useful in determining whether a given condition, e.g. , a pathogenic condition such as cancer, is due to abnormal levels of a Spry protein or to inactive form of the protein. The Spry protein is typically measured in the extracellular fluid of the tissue or organ of interest, e.g. , a solid tumor. Detection of Spry protein levels is preferably carried out by mixing the test sample with an antibody specific against a selected Spry protein. As described in the Materials and Methods, antibodies may be prepared by immunizing a host animal, such as a rabbit, with the purified polypeptide or fusion protein (generated using, for example glutathione-S- transferase as described above). The host serum or plasma is collected following an appropriate time interval, and the serum is tested for antibodies specific against the polypeptide. The gamma globulin fraction or the IgG antibodies of immunized animals can be obtained, for example, by use of saturated ammonium sulfate precipitation or DEAE Sephadex chromatography, affinity chromatography, or other techniques known to those skilled in the art for producing polyclonal antibodies. Alternatively, purified antigenic polypeptide or fused antigen protein may be used for producing monoclonal antibodies. In this case, the spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art (see, e.g. , Harlow, et al, 1988). Antibodies secreted by the immortalized cells are screened (see, e.g., using enzyme linked immunesorbent assay (ELISA) or a Western blot) to determine the clones that secrete antibodies of the desired specificity (see, e.g. , Ausubel, et al, 1988). The fluid sample is reacted with the antibody, to form a protein/antibody complex, and the mixture is then assayed for the presence/amount of complex. A variety of immunoassay formats suitable for this assay are known. It may also be desirable to assay the specific activity of the isolated protein. This can be done, for example, by treating the test sample to remove interfering substances, e.g. , FGF, and assaying the Spry protein activity of the purified or partially purified sample or Spry protein activity, e.g. , as described above. The results of the assay, assuming the test shows a lack of active Spry protein, either because the protein is produced at low levels or produced in an active form, are used to design a therapeutic strategy for supplementing or increasing the level of one or more Spry proteins, in accordance with the methods described below. VII. Therapeutic Applications It is known that unrestricted growth of tumors is dependent upon angiogenesis, and that induction of angiogenesis by liberation of angiogenic factors or loss anti-angiogenic factors can be an important step in tumorogenesis. The demonstration that certain animal tumors regress when angiogenesis is inhibited has provided compelling evidence for the role of angiogenesis in tumor growth (O'Reilly, et al, 1994). A. Spry Protein Therapy In one therapeutic application, the invention includes a method for inhibiting epithelial tube branching, e.g., angiogenesis, by administering a Spry peptide or polypeptide. In the method, pharmaceutically-effective dose of a the Spry peptide (e.g. , a peptide having the sequence represented as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO: 8) is delivered to the cells of a patient in need of treatment (e.g., tumor cells). In particular, methods of the invention may be used in the treatment of human patients having growing solid tumors with associated neovascularization or angiogenesis. Types of cancer suitable for treatment using methods and compositions of the invention include solid tumor cancers such as lung cancer, colon-rectum cancer, breast cancer, urinary tract cancer, cervical cancer, biliary tract cancer, brain cancer, choriocarcinoma, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasms, liver cancer, lymphomas, neuroblastomas, oral cancer, ovarian cancer, pancreas cancer, rectal cancer, sarcomas, skin cancer, testicular cancer, thyroid cancer, and renal cancer. Other disease states amenable to this treatment include, for example, diabetic retinopathy caused by vascular proliferation in the retina. According to this method, a sprouty polypeptide or fragment thereof ("stypep") is administered to the patient, preferably at site of the patient's tumor, in an amount sufficient to inhibit neovascularization, as evidenced, for example by inhibition of tumor growth. The Spry protein may be administered by any of a variety of methods known in the art, including oral, nasal insufflation, intraocular, parenteral, and anal and/or vaginal suppository administrations. Further, the stypep may be administered in a manner such that it arrives at the target site via the bloodstream extravascularly. Extravascular administration may be achieved by directly injecting or implanting the therapeutic peptide into the tumor using known techniques. For example, the peptide can be combined with slow release polymers such as poly-2-hydroxyethylmethacrylate or methylenevinylacetate copolymer. For skin tumors, the peptide can be combined with a topical ointment and applied directly to the surface of the tumor. Other procedures which may be useful include the preparation of the peptide in aerosol form for application to lung tumors, using standard devices employed by respiratory therapists to deliver aerosols. When a solid tumor is surgically removed, an implant may be placed at the site of the removed tumor, to inhibit angiogenesis of any reforming tumor at the same site. The required dose for lessening enlargement of a tumor will vary with the size and location of the tumor. Amounts may rang from 1 microgram (μg) to 1 milligram (mg). It is believed that preferred amounts will usually range from 100 μg to 800 μg quantities per dose. In general, an amount will be applied to the site of the tumor sufficient to retard growth of the tumor. The amount required for this purpose can be monitored by standard procedures. Where the tumor is still growing despite the application of the inhibitor, additional quantities will be administered. Preferably, a sufficient dose is utilized to substantially stop the increase of tumor size, or in some cases to decrease the size of the tumor. Such a result can be observed by a number of methods, depending on the location and type of tumor involved. These methods include: visual observation of surface tumors, palpitation, radiological measurement (using, e.g. , X-rays for lung tumors, mammograms for breast tumors, etc.), use of ultrasound with computer assisted tomographic scanners (CAT scans), magnetic resonance imaging, radionucleotide scanning, and other standard clinical techniques used to monitor particular tumor types. In addition to solid tumors, the inhibitors of this invention may be used as therapeutic agents for other diseases involving angiogenic dysfunction. These diseases include diabetic retinopathy, retrolental fibroplasia, neovascular glaucoma, psoriasis, angiofibromas, immune and non- immune inflammation (including rheumatoid arthritis), capillary proliferation within atherosclerotic plaques, hemangiomas, Kaposi's Sarcoma, endometriosis, and unwanted scar formation in wound healing. The amount to be used should be sufficient to partially or completely prevent the angiogenesis at the site where it is occurring. Several methods known in the art may be used to deliver such peptides or polypeptides. An exemplary delivery method employs liposomes (e.g, fusogenic liposomes) loaded with the selected peptide using standard known methods. The liposomes may further be constructed to contain a targeting moiety or ligand, such as an antigen, an antibody, or a virus on their surface to facilitate delivery to the appropriate tissue, such as a tumor. Methods for such targeting are known (see, e.g., Betageri, et al., 1993). The liposomes are delivered to the tissue by methods known in the art, for example, direct injection. Preferred liposomes have an average size of less than about 150 nm, to allow extravasation through capillary beds in tumor regions, and a surface coating of a hydrophilic polymer, such as polyethyleneglycol (PEG) effective to extend the circulation halflife of the liposomes sufficiently to allow liposome migration to and into the tumor site. In typical applications, the therapeutic compound is delivered to the target cells at regular intervals for the duration of treatment, which is determined by the attending physician. For example, a therapeutic peptide may be delivered once to several times daily in bolus injections containing between about 1 and about 100 μg peptide. If the peptide is contained in an encapsulant (e.g., liposomes), the amount of the suspension delivered is adjusted so that the selected pharmaceutically-effective amount of peptide is delivered. B. Gene Therapy The invention also includes gene therapy methods and compositions suitable for inhibiting epithelial tube branching, e.g. , in angiogenesis. In this aspect, a DNA sequence encoding a Spry polypeptide (e.g. , peptide SEQ ID NO:6 or SEQ ID NO:8) is cloned into an expression vector suitable for expressing the coding sequence in a tissue where inhibition of branching is desired (e.g., in a tumor). Molecular techniques and methods useful in the construction of expression vectors are well known in the art (e.g., Ausubel, et al , 1988; Sambrook, et al , 1989). A number of such vectors are known. They typically include at least one restriction site into which a desired coding sequence can be inserted, as well as a tissue-specific promoter operably linked to the coding sequence to control transcription of the coding sequence in the cell. Exemplary tissue-specific promoters for use in cancer therapy include the α-fetoprotein promoter for liver targeting, and the short metallothionein promoter for neoplasms, such as B-cell neoplasms, expressing immunoglobulin enhancer. The constructs can be tested by transfecting suitable animal models, e.g., tumor models such as the nude mouse model of Ossnowski, et al , 1991. Any of a number of methods known to those skilled in the art may be used to introduce gene therapy vectors of the present invention into selected target tissue cells, e.g. , tumor cells. For example, the vectors may be introduced using viral-mediated gene transfer. In this technique, host cells are trasfected by infection with mature virions containing hybrid vectors (constructs encoding Spry along with selected viral sequences). The virions used to transfect host cells are preferably replication-defective, such that the virus is not able to replicate in the host cells. The virions may be produced by co-infection of cultured host cells with a helper virus. Following coinfection, the virions are isolated (e.g., by cesium chloride centrifugation) and any remaining helper virus is inactivated (e.g., by heating). The resulting mature virions contain a construct or chimeric gene of the present invention and may be used to infect host cells in the absence of helper virus. Alternatively, high titers of replication-defective recombinant virus, free of helper virus, may be produced in packaging cell lines containing those components for which the virus is defective. Alternatively, the vector construct can prepared as a gene therapeutic composition, for example, by complexing the DNA vector with a polycationic agent, such as polylysine, preferably in an amount sufficient to produce stoichiometric charge neutralization, e.g. , a 1: 1 charge ratio. The polycation may be additionally conjugated with a targeting agent, e.g. , a tumor-antigen-specific binding agent, for tumor targeting. Methods for producing DNA-polylysine-targeting moiety complexes of this type, in the 40-150 nm size range are well known. The therapeutic complex can be administered by a variety of methods, including intravenous injection, catheter delivery, or direct injection into a tumor mass, or ex vivo transfection of tissue or blood cells. The following examples illustrate but in no way are intended to limit the present invention. MATERIALS AND METHODS Unless otherwise indicated, all reagents were purchased from Sigma Chemical Company (St. Louis, MO). Abbreviations used below include the following. PAGE: polyacrylamide gel electrophoresis; SDS: sodium dodecyl sulfate; BSA: bovine serum albumin. A. Fly Strains and Genetics Three P-element insertions in the Spry locus (Spry 2m , Spry ι and Spry 9i43 ) were identified in an enhancer trap screen and were referred to as the Pantip-2 markers (Samakovlis, et al, 1996). Spry 2 is homozygous viable and shows normal tracheal branching. Spry m and Spry 1814 contain a P[lacZ,w+] element (Bier, et al, 1989) at 63D1,2. Spry 9143 contains a P[lacZ,ry+] element. B. Antibody. BrdU and TUNEL Staining Embryos were fixed in formaldehyde, devitellinized in methanol and stained with antibodies as described (Samakovlis, et al , 1996). Embryos were stained with the following antibodies: mouse IgM mAb 2A12 against an anonymous tracheal lumenal antigen (1:5; Samakovlis, et al , 1996); rabbit polyclonal antiserum against beta-galactosidase (1: 1500; Cappell, Durham, NC); mouse IgG mAb against Drosophila serum response factor (1: 1000; Guillemin, et al , 1996); mouse IgG mAb against Notch protein (1 :3000). Biotin-, Cy5-, Cy3- or FITC-conjugated secondary antibodies, obtained from Jackson Immunoresearch (West Grove, PA), were used at 1:300. HRP histochemistry was performed with "VECTASTAIN" ABC kit (Vector Laboratories, Burlingame, CA). 5-bromodeoxyuridine (BrdU) and terminal deoxyribonucleotidyl transferse (TdT)-mediated biotin- 16-dUTP nick-end labelling (TUNEL) staining were done as previously described (Samakovlis, et al, 1996) using wild type and Spry* 5 embryos from stages 10 to 16. C. Molecular Analysis of Spry Mutants Defects in the Spry excision mutants were determined by analyzing genomic Southern blots of wild type and mutant genomic DNA probed with genomic fragments flanking the P element insertion site, the full P[lacW] element, and the Spry cDNA 12.2. To identify mutations in the EMS-induced mutants, the complete coding sequence and 122 bp of flaking DNA in the Spry locus was determined by cycle sequencing (femtomol cycle sequencing, Promega) of PCR-amplification products of genomic DNA from the mutants. Genomic DNA was isolated from third instar larvae carrying a Spry EMS-allele over Df(3L)HR119 (Lis, et al , 1983). Two independent PCR-products were sequenced for each allele. D. Antibody Production and Staining Full-length (nucleotides (nt) 1323-3098), N-terminal (nt 1509-2708) and C-terminal (nt 2772-3098) coding fragments of the Spry 12.2 cDNA were amplified by PCR and inserted 3' of the GST coding sequences in pGEX-4T-2 (Pharmacia Biotech, Piscataway, NJ). Spry fusion proteins were purified by glutathione affinity chromatography (Pharmacia) and injected into rabbits and mice at Josman Labs (Napa, CA). Antisera were affinity-purified using full-length GST-Spry fusion protein coupled agarose beads (Pierce Chemical, Rockford, IL). Antisera were preabsorbed overnight at 4°C against 0-2hr fixed embryos and used the supernatant was used at 1:500-1: 1000 for embryo staining and 1:5000-1 : 10000 for immunoblots. Antiserum 26A was generated using the full-length Spry fusion protein. 0.25 micrograms of the fusion protein were injected in Freund's adjuvant five times at two week intervals. Serum was collected one week after final injection. EXAMPLE 1 Spry Mutagenesis The mutant Spry 2m , which shows normal tracheal branching (see Materials and Methods, above), was used in mutagenesis studies as follows. Excisions of the P[lacW] insertion in Spry 2683 were generated by crossing in a third chromosome carrying Δ2-3 to supply transposase. 100 white-eyed males from independent excision events were isolated and established as balanced stocks over a balancer chromosome carrying a Ubx-lacZ transgene. Adult progeny of these stocks were scored for the presence of a lethal mutation on the third chromosome. Embryos collected from each stock were stained with the tracheal lumenal antibody mAb 2A12 and anti-/3-galactosidase antiserum, and scored for tracheal defects under DIC optics. Of the 100 excision lines, 12 were homozygous lethal, 5 were lethal with occasional escapers, 24 were semilethal and 56 were viable. Three excision alleles (5, 64, 55) formed a lethal complementation group that was lethal over deficiencies in the region and exhibited similar recessive tracheal defects. Chromosomal deficiencies Df(3L) Hr232, Df(3L) Hrl l9 and Df(3L) Hr298 (Wohlwill and Bonner, 1991) and Df(3L) 1226 and Df(3L) 1227 (Lindsley and Zimm, 1992) uncover the 63D1.2 region. 1226 did not complement the lethality or tracheal phenotype of Spry alleles and Southern analysis showed that it removed all Spry exons. Hr298 did not complement Spry for tracheal phenotype but was not tested for lethality or molecular lesions. Hr232, 119 and 1227 partially complemented the Spry alleles for lethality and tracheal phenotype. Five EMS-induced Spry alleles (.Spry 254 , Spry 211 , Spry 226 , Spry 05 ' Spry* 1 ) were identified in a screen for dominant suppressors of the rough eye phenotype caused by ectopic expression of seven-up in photoreceptors R2 and R5 (Kramer, et al , 1995). The terminal cell lacZ markers used were Term- 1 (prunedlSRF, (Guillemin, et al. , 1996)), Term- 2, Term-3, and Term-4 (Samakovlis, et al , 1996). The enhancer trap used for monitoring Spry expression was Spry 9143 because it had the strongest lacZ expression. The other Spry enhancer trap lines showed the same expression pattern, and all agreed with the whole mount mRNA in situ expression using a Spry cDNA probe (Example 7). The string-lacZ line (Edgar, et al , 1994) has lacZ expression in dividing tracheal cells. The H99/TM6b, deficiency, which removes several genes required for cell death (White, et al , 1994), was used to eliminate cell death. EXAMPLE 2 Ectopic Branching in Spry Mutant Embryos The effects of Spry mutants on tracheal morphology was assessed using immunohistochemical lumenal staining with mAb 2A12. Exemplary results are presented in schematic and photomicrograph forms in Figs 1 and 2, respectively. The fifth tracheal unit of the developing wild-type Drosophila tracheal system is schematized at different developmental stages in Figs. 1A, IB and lC. The fifth tracheal unit, like the other repeating tracheal units, develops via unicellular branches. The tracheal lumen is outlined in black, nuclei of tracheal cells are in gray and nuclei of cells that form fine branches are filled in black. At stage 12 (Fig. 1A), six primary branches are growing out from fixed locations. By stage 16 (Fig. IB), the primary branches have reached their final positions and individual terminal cells begin to form fine (secondary) branches. In third instar larvae (Fig. IC), each terminal cell ramifies to form terminal branches. As discussed above, this normal branching pattern is disrupted in Figs. 2A/2B and 2E/2F are whole-embryo/close-up photomicrographs of such primary and secondary branches in wild type (+) embryos at stage 16; Figs. 2C/2D and 2G/2H show the corresponding branches in Spry* 5 (Spry) embryos. Dorsal branches (DB) on both sides of embryo are visible in the dorsal views shown in Figs. 2A-2D. Note the extra branches in Spry* 5 embryos (Figs. 2C/2D). Fig. 2B shows a close-up of one dorsal branch in wild-type, with one fine branch (arrowhead). A corresponding dorsal branch in Spry* 5 has three fine branches (Fig. 2D). Figs. 2E/2F and 2G/2H are ventral views showing ganglionic branches (GB). Figs 2F and 2H show close-up of one ganglionic branch with one fine branch in wild-type (Fig. 2F) and two fine branches in Spry* 5 (Fig. 2H). Note that all ectopic fine branches are found nearby the normal branches. Lumen that is outside the focal plane is marked in Figs. 2A, 2C, 2E and 2G by a dashed line. Scale bars in Fig. 2G (for Figs. 2A, 2C, 2E, and 2G) and in Fig. 2H (for Figs. 2B, 2D, 2F, and 2H) are 10 μm. Five EMS-induced Spry alleles (Spry 254 , Spry 211 , Spry 216 , Spry G5 - Spr 1 ) were recovered in an unrelated screen for mutations that suppress a dominant eye phenotype (Kramer, et al , 1995). All the alleles mapped to the same genetic interval in the 63D region and had the same tracheal phenotype as Spry' 15 (Table 1, below). Spry 254 was tested and failed to complement the three original Spry alleles for tracheal function and lethality. Molecular analysis of all the EMS mutants identified lesions in Spry coding sequences (see below). All eight Spry mutations resulted in pupal lethality in trans to deficiencies in the 63D region including Df(3L) 1226, Df(3L) 1227, Df(3L) Hrl l9, Df(3L) Hr232. Spry* 5 homozygotes displayed as severe a tracheal phenotype as Spry* 5 VDf(3L) 1226 and Spry^/Df (3L) Hr298, indicating that Spry* 5 is a strong loss-of-function or null allele (Table 1, below). Table 1 Tracheal Defects in Spry Alleles Average number of DSRF-expressing fine branching cells per primary dorsal (DB) or ganglionic (GB) branch. Embryos were stained with mAb 2A12 to visualize tracheal lumen, anti-SRF to mark branching cells, and anti-β-gal to distinguish homozygous mutants from balanced embryos expressing Ubx-lacZ from the TM3 chromosome. n = the number of tracheal segments counted. EXAMPLE 3 Distribution of Cells and Expression of Branching Markers in the Wild Type (+) and Spry* 5 Mutant Tracheal Systems The distribution of cells and expression of branching markers in the wild type ( + ) and Spry* 5 mutant tracheal systems was compared. The results are shown in Figs. 3A-3L. Figs. 3 A and 3B are photomicrographs showing dorsal branch expression of a pantracheal lacZ marker (6-81a or btl-lacZ) in wild type (Fig. 3A) and Spry* 5 (Fig. 3B) embryos. Figs. 3C and 3D are tracings summarizing such expression in the ganglionic branch of wild type (Fig. 3C) and Spry* 5 (Fig. 3D) embryos. Arrowheads indicate fine-branching cells. Figs. 3E-3J are photomicrographs employing the Drosophila serum response factor (DSRF) marker, which is expressed in the nuclei of fine-branching cells in both wild type embryos and in Spry* 5 embryos. Fig. 3E is a dorsal view of a wild-type embryo showing two primary dorsal branches, with one terminal cell (arrowhead) in each branch. Fig. 3F is a dorsal view of a Spry Δ5 embryo at stage 16, showing dorsal branches, each with two terminal marker expressing cells. Fig. 3G shows a wild-type ganglionic branch at stage 16, with one terminal cell. Fig. 3H shows a Spry Δ5 ganglionic branch at stage 16, with two terminal cells. Fig. 31 shows a wild type ganglionic branch at stage 13, with one terminal cell, at the point when the terminal marker just begins to turn on. Fig. 3J shows a Spry" 15 ganglionic branch at stage 13, with two terminal cells. Fig. 3K is a larval view photomicrograph of two wild type larval dorsal branches (DB), each with one terminal cell that gives to rise to an extensively ramified branch (arrowhead). Fig. 3L is a photomicrograph of a Spry* 5 type larval dorsal branch terminal cell, with two terminal cells giving rise to further branches. Scale bars in Fig. 3 A (for Figs. 3A-D), Fig. 3E (for Figs. 3E-F) and Fig. 3H (for Figs. 3G,J) are 5μm. Scale bar in Fig. 3L (for Figs. 3K-L) are 10 μm. Taken together with the data in Example 2, the above results indicate that the extra branching in Spry* 5 mutants was due to an increased number of branch-forming cells rather than an increased number of branches formed by the normal group of branch-forming cells. Staining of Spry' 15 mutant embryos with a nuclear marker expressed in all tracheal cells showed that there was a parallel increase in the number of branch-forming cells, each associated with an extra branch (Fig. 3B, D). The results do not suggest that the extra branching cells in Spry mutants arise from excess cell proliferation, diminished cell death or ingression of cells from other tissues. It is unlikely that additional cell division in the mutants could have generated the extra branching cells, since cell counts showed that although the total number of cells in a typical hemisegment (Tr5) that formed fine branches increased from - 20 to - 30 in the Spry* 5 mutant, the total number of tracheal cells was not correspondingly increased (78+/-4 cells in wild typeTr5 (n=6) vs. 73 +/-3 in Spry* 5 Tr5 (n=3)). Furthermore, no additional dividing cells were detected in Spry* 5 embryos by labeling with BrdU or a string-lacZ marker that expresses lacZ in dividing cells. The extra branching cells are also unlikely to have arisen from suppression of normal cell death since cell death does not appear to occur during wild type tracheal development (Samakovlis, et al , 1996) and no extra branches were observed in the H99 deficiency mutant which prevents all normal cell death (White, et al , 1994). The above results do indicate, however, that the extra branching cells arise by the conversion of non-branching tracheal cells into branch-forming cells. As shown in Figs. 3F and 3H, the ectopic branching cells in Spry mutants expressed the normal secondary and terminal branch markers, and these markers were activated at the same time as in normal branch forming cells (Fig. 3J). Cells at the corresponding position in wild type trachea did not express these markers (Figs. 3E, 3G and 31). The ectopic branching cells in Spry mutants also followed the same developmental program as the normal branching cells, extending long cytoplasmic processes in parallel directions and forming extensive networks of terminal branches in the larva (Figs. 3K and 3L). Thus, by all available criteria, the ectopic branch forming cells in S ry^ mutants were indistinguishable from the normal branch-forming cells. EXAMPLE 4 Genetic Mosaic Analysis of Spry in the Developing Tracheal System A genetic mosaic analysis of Spry in the developing tracheal system was carried out to determine in which cells the Spry gene functions to inhibit branching. The Spry'" mutation was recombined onto the left arm of a third chromosome carrying a FLP recombination site (FRT) near the centromere (Xu and Rubin, 1993). 1-eve-l, a lacZ enhancer trap marker at 61E expressed in all tracheal cells (Perrimon, et al , 1991), was recombined onto a separate FRT third chromosome. The 1 -eve- 1 -FRT chromosome was crossed into hsFLP;Dr/TM3ry flies, which carry FLP recombinase under heat shock control. Resulting progeny carrying hsFLP and 1 -eve- 1 -FRT were crossed to Spry^-FRT/TM3 to give progeny of the genotype hsFLP;l-eve-l-tocZ FRT/Spry^-FRT. hsFLP;l-eve-l-/αcZ FRT ' I Spry* 5 FRT embryos were collected at late stage 10 and early stage 11 at 25 °C and heat-shocked twice at 37 °C for 20 min at 5 and 6 hours AEL (after egg laying). Clones were observed 10 hours later (stage 15 or 16) after fixation and staining with the mAb 2A12 lumenal antibody and anti-0-galactosidase antiserum. Tracheal cells from 1-eve-l that expressed cytoplasmic β-galactosidase ( / S-gal) were identified as Spry + ; cells that did not express 0-galactosidase ( / S-gal), but that often had a thin lumenal stain, were identified as Spry " (Spry* 5 1 Spry* 5) . Thirty six clones were identified in the dorsal and ganglionic tracheal branches. The clones and surrounding cells were carefully examined for tracheal defects. Clones were found in — 12% of embryos of the correct genotype. Although a small number of clones were examined in the dorsal branch (DB), the analysis was focused on the ganglionic branch (GB) due to its simple structure and relative ease of determining cell identities and branching fates. In wild type embryos, the GB is composed of seven cells that grow toward the ventral nerve cord. The lead cell (GB1) always expresses secondary and terminal markers and forms fine branches, while the other six cells (GB2-7) do not express secondary or terminal markers and do not form branches. Exemplary results are shown in the photomicrographs of Figs. 4A, 4B and 4C, showing mosaic clones of Spry and wild type cells distinguished by expression (Spry + ) or lack of expression of cytoplasmic / S-gal (Spry ). Fig. 4 A shows an ectopic branch arising from GB2 when there was no / 3-gal expression in the leading cell (GB1) of the ganglionic branch. Neighboring segments had GB1 cells with / S-gal expression and no ectopic branches. Twenty nine such clones were analyzed. Fig. 4B illustrates a situation where no ectopic branch was seen when no /3-gal expression was present in the second cell (GB2) of the ganglionic branch. Four such clones were analyzed. In Fig. 4C, ectopic branches are seen arising from DB3 and DB4 when there is no / S-gal expression in the leading cell (DBl) of the dorsal branch. Only four clones were found in GB2-7, presumably because the cells were crowded together and overlapped in space. The edge of the ventral nerve cord is marked with a white dashed line. Scale bar is 10 μm. The above results demonstrate that Spry acts non-autonomously to inhibit tracheal branching. In the 29 clones in which just the GB1 cell was Spry ' , an ectopic branch was always present in the neighboring GB2 cell (Fig. 4A). Furthermore, three of the four identified clones of the opposite type in which non-leading cells (GB2-7) were Spry " , the ganglionic branch appeared normal with no extra branches (Fig. 4B). One particularly informative Spry ' clone of this type included all cells of the GB except the lead cell; this formed a normal ganglionic branch without ectopic branches. The data thus show that Spry + is required in the GB1 cell of the ganglionic branch and acts non-autonomously to inhibit branching in the neighboring cell. Although data for the dorsal branch (DB) were more limited, they supported the results from the ganglionic branch. In the four clones in which the lead cell of the dorsal branch (DBl) was Spry ' , neighboring cells appeared to form ectopic branches. In the clone shown in Fig. 4C, for example, both the DB3 and DB4 cells inappropriately extended branches. There were two unexpected characteristics of the Spry ' clones in which the GB1 cell was mutant. First the outgrowth of the ectopic branches tended not to follow the same outgrowth pathway as when the entire animal was Spry " ; they typically turned away from the ventral nerve cord (Fig. 4A) whereas the extra branches in Spry embryos normally enter the cord (Fig. 2C). This indicates that Spry + cells in the mosaics somehow influenced branch pathfmding. Second, the outgrowth of the normal branch from the GB1 cell appeared to be inhibited in clones in which the GB 1 cell was Spry " but the neighboring cells (GB2-7) were Spry + . This suggests that Spry "1" also has a cell-autonomous function that prevents inhibition of branching by its Spry + neighbors, an interpretation supported by experiments described below in which Spry protein was ectopically expressed. EXAMPLE 5 Genomic Analysis and cDNA Cloning of the Spry Locus A. Genomic Cloning Genomic DNA flanking the P-element insert in Spry 2m was recovered by plasmid rescue using standard protocols (Bellen, et al. , 1989) following digestion of genomic DNA with BamHl or EcoRl. An 8kB Hindlll/BamHl genomic fragment from a BamHl rescued plasmid (5B) was used as a probe to screen — 10 5 phage from a Drosophila genomic library in EMBL3, and genomic phage were isolated and placed into a contig by restriction mapping and cross hybridization with each other and with plasmid rescues on Southern blots. The results are summarized in Fig. 5 A, which shows a diagram of the Spry genomic locus and gene structure. A genomic map of £cøRI (R) and Sail (S) restriction sites was assembled from the BamHl plasmid rescue and overlapping genomic phage clones ( 3.5, 1.1, 1.2; shown at the bottom of the panel) and is represented on the top horizontal line. The insertion of the original P element, Spry 26 ^, is marked with a triangle, which lies 0.6 kb upstream of the class I cDNA. The origin (0 kb) is where the Spry transcription unit begins, based on mapping the 5' end of the largest class of cDNAs. Three distinct cDNA forms were isolated and mapped onto the genomic contig of the region by the use of genomic Southerns, PCR and DNA sequencing. Exons are indicated by boxes; a filled-in box is an open reading frame; an unfilled box is an untranslated region. In the longest cDNA, the open reading frame is preceded by a 1.2 kb 5' UTR and followed by a 200 bp 3' UTR with a poly A tail. The extents of the deletions in two strong excision mutants (Spry* 5 and Spry* 64 ) are indicated by short vertical lines; the common 5' exon is deleted in these mutants. B. Isolation and Characterization of cDNAs The 8kb Hindlll/BamHl genomic fragment described above was also used to screen - 10 6 phage from a size-selected 9-12 hour embryonic cDNA library in λgtl l (Zinn, et al. , 1988). The eleven cDNA clones isolated fell into three size classes: class I (3.2 kb; clones 3.1, 12.2), class II (2.8 kb; clones 2.4, 3.5, 11.1, 12.4, 13.1, 13.2, 13.3, 13.5 ) and class III (1.7 kb; clone 11.3). The size classes correspond to the three splice forms shown in Fig. 5A. The assignment of classes was verified by cross-hybridization and restriction enzyme analyses. Several cDNAs (clones 12.2, 11.3 and 13.3) were sequenced on both strands using Sanger dideoxy sequencing methods (United States Biochemical, Cleveland, OH). Exons were mapped by hybridization of cDNA fragments to digested genomic phage DNA. Intron/exon boundaries were determined by PCR analysis of genomic DNA using primers from the cDNAs and by sequencing the relevant regions of genomic DNA. These cDNAs were verified as corresponding to the Spry transcription unit as follows. First, whole mount mRNA in situ hybridization using the 3.2 kb cDNAs as probes detected an expression pattern that corresponded precisely to the lacZ pattern found for the four extant Spry enhancer trap lines (Example 7), and expression in the developing tracheal system was consistent with the genetic mosaic analysis of Spry function (Example 4). Second, molecular analysis of Spry mutations revealed deletions and non-sense mutations in the identified transcription unit in all eight Spry alleles. In the two strong Spry excision alleles (Spry* 5 , Spry Δ64 ) the 5' exon common to all splice forms was deleted (Fig. 5A), and in the weaker excision allele (Spry* 55 ) there was a complex rearrangement that included this exon. Sequence analysis of the EMS alleles revealed non-sense or frameshift mutations in each of the five alleles (Spry 54 , Spry 211 , Spry 226 , Spry G5 - Spr 1 ) that would result in truncated polypeptides lacking all or most of the conserved motif described below. Third, ectopic tracheal expression of the cloned cDNA inhibited tracheal branching, as expected from the genetic analysis (Example 8). And finally, using antisera raised against the Spry protein, no Spry protein was detected in Spry^ eye imaginal discs. Fig. 5C shows the polynucleotide sequence of cDNA clone 12.2. The 5'- and 3'- untranslated regions are designated by small letters. The four nucleotides, CTAC, preceding the ATG match at 3/4 bases to the consensus start site [C/A]AA[A/C]. Several stop codons are located upstream and in frame to the ATG. The position of single base nonsense mutations are marked as grey circles on the base that is altered. The changes in the mutants are as follows: in 226 C 2055 → T; in 211 C 2253 → T; in G5 G 2710 → A; in F7 C 2466 → T. Spry 254 has a small deletion from 2237-2243 (grey oval) and an insertion of two nucleotides (TA) following A 2236 . As is shown in Fig. 5C, clone 12.2 is composed of two exons which are joined at the narrow arrowhead (between nt 1126 and nt 1127). The second (2.2 kb) exon contains a single long open reading frame (ORF). The broad arrowhead between nt 467 and 468 indicates an alternative start site that generates the smaller transcripts of class II (such as cDNA 13.3). MISSING UPON TIME OF PUBLICATION C. Identification of Sprouty Homologs An NCBI BLAST search of the combined databases did not detect any closely related proteins. However, a search of the expressed sequence tag (dbEST) database identified three human homologs referred to herein as hSpryl (SEQ ID NOs:5, 6) (clone 5 142025, IMAGE consortium clones, Lennon, et al, 1996), hSpry2 (SEQ ID NOs:7,8,9) (clone 40262), and hSpry3 (SEQ ID NOs:10,l l; clone XAP128). A complete coding sequence was determined for hSpryl (40262) (SEQ ID NO:7) and a partial sequence was determined for hSpryl from overlapping cDNAs (142025, 78383 and 727987), (SEQ ID NO:5). 0 The hSpryl sequence predicts a 315 residue polypeptide with a mass of 35 kD. It contains a cysteine-rich domain which is highly conserved with Spry (51 % identity with 21 of the 22 Spry cysteines conserved) and two additional short stretches of similarity with Spry in the N-terminal region. hSpryl and hSpry3 also show strong conservation of the cysteine-rich domain, with 51-70% identity to other family members in the available 5 sequences. Additional mouse ESTs found to be part of the sprouty gene family included mSpryl, SEQ ID NOs: 12,13 (907842), mSpry2, SEQ ID NO: 14 (819774) and mSpry4, SEQ ID NOs: 15, 16 (919795). An alignment of the full hSpryl sequence and partial sequences of hSpryl and 0 hSpry3 with the Drosophila Spry sequence is shown in Fig. 5D. D. Northern Analysis The 8kb Hindlll/BamHl genomic fragment described above and cDNA clone 12.2 were used to probe developmental Northern blots of embryonic mRNA. The mRNA was 5 prepared by standard phenol/chloroform extraction of total RNA (Sambrook, et al, 1989) from 0-1.5, 1.5-5, 5-11, 11-16, 16-22 hour embryos at 25°C followed by selection on oligo-dT paramagnetic beads (Promega, Madison, WI). PolyA + RNA was transferred to a "HYBOND" filter (Amersham, Arlington Heights, IL) and probed with radiolabelled cDNA 12.2 or 8kb clone. Exemplary results are shown in Fig. 5B. Three species between 3.2 and 4.4kb were detected using the cDNA 12.2 probe. As can be appreciated from the figure, the mRNAs turned on just after tracheal development began and continued to be expressed throughout the period of tracheal development. EXAMPLE 6 Localization of Spry Protein to the Plasma Membrane Spry protein distribution was analyzed using affinity-purified antiserum 26 A, which was raised against full-length Spry protein. Although this antiserum was not sensitive enough to reproducibly detect the endogenous Spry expression pattern in embryos, specific expression was detected in intracellular vesicles and cell membranes in developing eye discs where Spry has been shown to function. To determine the subcellular localization of Spry in tracheal cells, Spry was overexpressed in C38;UAS-Spry embryos using the GAL4/UAS system. The dorsal trunk and branches were stained at stage 14 with antiserum 26A, shown as red staining in Fig. 6A. The same dorsal trunk was also stained with anti-Notch antibody, shown in green (Fig. 6B). The two images are shown merged in Fig. 6C, with yellow staining representing co-localization of Spry and Notch proteins. Scale bar in Figs. 6 A and 6B is 5 μm. As can be appreciated from the figures, Spry (red) staining was localized at or near the surface of tracheal cells. Further, this staining co-localized with the (green) staining of the control trans-membrane protein Notch (Figs. 6B and 6C). These data support the conclusion that Spry is a membrane bound or secreted protein. EXAMPLE 7 Level of Spry Expression in the Branch-Forming Tracheal Cells The embryonic expression pattern of Spry was determined by whole-mount in situ hybridization using a 3.2 kb (clone 12.2) Spry cDNA as a probe, and by analysis of the three Spry enhancer trap inserts as described above. The enhancer trap inserts closely mimic mRNA expression but provide greater cellular resolution. In situ hybridizations were performed by fixing and processing wild type embryos using standard methods (Tautz and Pfeifle, 1989). An 8kb Hindlll/BamHl genomic fragment and a 3.2 kb cDNA clone (clone 12.2), described above, were labelled by random priming with digoxigenin labelled nucleotides and used to probe the embryos. The results are shown in Figs. 7A-7H. The photomicrographs in Figs. 7A-7D show the timecourse of Spry-lacZ expression in Spry 9143 embryos in the dorsal branch. Fig. 7E shows Spry mRNA expression at stage 14 in the visceral branches (VB) and (G) midline glia (MG, dashed circle). Fig. 7F shows Spry-lacZ expression at stage 15/16 in VB and (H) MG. Arrowhead shows the GB1 staining which is not detectable by mRNA staining before stage 15. Figs 7G and 7H show expression of Spry in midline glial cells. Scale bars in Fig. 7 A (for Figs. 7A-D) and Fig. 7G (for Figs. 7E-H) are 5 μm. The results show that Spry is expressed specifically in the tracheal system and other tissues, including the midline glia (Fig. 7H), a group of neurons in the VNC, the dorsal vessel, oenocytes, and the eye imaginal disc. Tracheal expression was first detected in all primary branches as they began to bud, and was maintained at high levels in the primary branch cells that go on to form secondary and ultimately terminal branches. Expression in the dorsal branch is shown in Figs. 7A-D. At stage 12 Spry was expressed in two cells (DBl, 2) at the leading edge of the dorsal branch and less intensely in two more proximal cells (DB3, 4) (Fig. 7A). At stage 13, there was a gradient of Spry expression, with highest expression in the two leading cells of the branch (Fig. 7B), which begin to separate such that each forms a discrete branch. From stages 13 to 15, Spry was expressed most strongly in the DBl cell (Fig. 7C), and was ultimately expressed in this cell alone (Fig. 7D); this is the cell that goes on to form fine terminal branches in the late embryo (stage 16/17) and throughout larval life. Taken together, these results indicate that Spry is expressed at high levels in the branch-forming tracheal cells. EXAMPLE 8 Effect of Spry Ectopic Expression on Tracheal Branching The GAL4-UAS expression system (Brand and Perrimon, 1993) was used to test the 5 effect of expressing Spry at uniform levels throughout the developing tracheal system. A transgenic line was made containing Spry under the control of UAS elements, which can be driven by the GAL4 protein, as follows. A 2.2kb EcoR fragment from cDNA 12.2 containing the entire Spry ORE was inserted into the pUAST vector (Brand and Perrimon, 1993) at the EcoRl site downstream 10 of the promoter and Gal4 UAS binding sites to generate pU AST-Spry S2.2. The construct, along with pΔ2-3 (a transposase-expressing plasmid; Robertson, et al. , 1988), was injected into w 1118 embryos. Six independent lines were generated, and an insertion on the third chromosome, UAS-Spry 4.1, was used for overexpression experiments. Similar results were obtained with the independent insertion UAS-Spry 1.3. The Gal4 driver lines used 15 were hsGal4 (Brand and Perrimon, 1993) and C38, a pantracheal driver expressed from early stage 13 onwards (Lin and Goodman, 1994). The results are shown in Figs. 8 A, 8B and 8C. Fig. 8 A shows wild-type DSRF (terminal cell marker) expression in terminal cells (arrowheads). Fig. 8B shows early (stage 10/11) misexpression of Spry with a hsGal4 driver suppresses DSRF expression 20 (shown at stage 14) and subsequent terminal cell branching. Fig. 8C shows that expression of Spry at later times (stage 12) results in ectopic expression of DSRF shown at stage 14 and outgrowth of terminal branches (inset at stage 16) in some segments. Scale bar in Fig. 8A (for Figs. 8A-8C) is 5 μm, in inset of Fig. 8C, 10 μm. As can be appreciated, when Spry expression was induced at stage 11 and at stage 25 12 using a heat-shock-Gal4 strain, the branching throughout the tracheal system was inhibited, as assayed by expression of the DSRF terminal branching marker (Fig. 8B). This was expected given the excessive branching observed in the Spry loss-of-function mutants. Surprisingly, when expression of Spry was induced at stage 13 or beyond using the hsGAL4 driver or a tracheal specific driver, branching was not inhibited. Indeed, extra 30 DSRF-expressing cells were occasionally found in some embryos (Fig. 8C). Thus, expressing high levels of Spry early inhibits the branching program while expression at stage 13 and beyond may paradoxically stimulate branching. A model described below that reconciles these results supposes that Spry has two functions: a cell non-autonomous function as an inhibitor of branching, and a cell autonomous function which normally 35 protects the expressing cells against the inhibitory activity. EXAMPLE 9 Effect of Spry Mutations on Downstream Effectors in the Bnl Signalling Pathway A. General Approach Secondary and terminal branching genes are induced at the ends of growing primary branches by localized expression of the Bnl FGF in surrounding tissues (Sutherland, et al. , 1996). Since the ectopic branches in Spry mutants are formed by the pre-stalk cells located just beyond the cells that are normally induced to branch, the extra branches could arise from overactivity of the Bnl pathway. To determine whether Spry+ functions by limiting the Bnl pathway or whether it prevents branching in some other way, the following experiments were conducted to examine the effect of Spry mutations on downstream effectors (pnt, Yan, DSRF gene) in the Bnl pathway that regulate the later branching events. The results are illustrated in the computer-generated images corresponding to Figs. 9A-P. B. Fly Strains and Genetics The following null or strong loss-of-function alleles were used: Bnl n (Sutherland, et al, 1996), btl LG18 and btl LG ' 9 (Klambt, et al, 1992), pnt* (Scholz, et al , 1993), and yan 5433 . The PflacZ] enhancer trap markers used were /zt 7825 (Samakovlis, et al , 1996), 5"81 (Bier, et al , 1989; Samakovlis, et al , 1996), yan* (Lai and Rubin, 1992), Terminal-1 (pruned/DSRF), -2, -3, and -4 (Guillemin, et al, 1996; Samakovlis, et al, 1996), 1-eve-l (Perrimon, et al , 1991), and Spry 9143 . Spry 9143 was chosen because it has strongest lacZ expression, although the other Spry enhancer trap lines show the same pattern. The string-lacZ transgene P[w+]STGb6C from B. Edgar was used to monitor tracheal cell division. C. Antibodies mAb A2 8B12 against Yan (1:5) D. Misexpression of Spry and other genes in vivo Gal4 driver lines employed were hsGal4 (Brand and Perrimon, 1993), and C38 (Lin and Goodman, 1994) and TrGal4 which express GAL4 in all tracheal cells from stage 13 on. The UAS-Spry lines were constructed by inserting the 2.2 kb EcoRl fragment from cDNA 12.2 containing the full Spry coding sequence into the P element vector pUAST and generating transformant lines. Insertions on the second (UAS-Spry4.1 #2) and third (UAS-Spryl.3 and UAS-Spry-6.2) chromosomes were used with similar results. Other UAS strains were UAS-pntPl .3 (Klaes, et al , 1994); and UAS-Bnl (Sutherland, et al , 1996). For experiments with the hsGal4 driver, eggs were collected for - 7 hours at 25°C, aged for 4 hours at 25°, heat shocked twice at 37° for 20 min separated by a 1.5 hr recovery, and then aged six hrs at 25° . For experiments with C38 or TrGal4 drivers, eggs were collected for 6 hrs at 25° and aged at 29° for 9 hours. 1. Effect of Spry mutations on expression of the Bnl-induced genes pnt and Spry. One effector tested was pnt, a downstream target of several receptor tyrosine kinase (RTK) pathways (Brunner, et al , 1994; O'Neill, et al , 1994; Gabay, et al , 1996). Pnt expression is induced by Bnl at the ends of primary branches and promotes secondary and terminal branching (Samakovlis, et al. , 1996; Sutherland, et al , 1996; Fig. 2A, D). Figs. 9 (A-E) illustrate the effect of Spry mutations on expression of the Bnl- induced genes pnt and Spry. The /zt 7825 and Spry* 55 enhancer trap markers (as described above) were used as reporters and mAb2A12 was employed to label the tracheal lumen. Fig. 9 A corresponds to wild type DB, stagelό, where high level expression of pnt is seen only in DBl. Fig. 9B corresponds to Spry* 5 homozygote. Pnt is ectopically induced in DB3. Fig. 9C illustrates the Spry* 55 ' I Spry* 64 loss of function mutant. The results indicate that the Spry reporter is ectopically induced in DB3. Fig. D corresponds to wild type GB, stage 16. High level expression of pnt is seen only in GBl . Fig. 9E corresponds to S ry^ homozygote, where pnt is ectopically induced in GB2. 2. Effect of Spry mutations on expression of DSRF. Figs. 9F-K illustrate the effect of Spry mutations on expression of DSRF, a Sλzi-induced gene that controls terminal branching. Fig. 9F corresponds to wild type DB, stage 16. DSRF expression (mAb2-161) is seen only in DBl . Fig. 9G corresponds to Spry'" homozygote. DSRF is ectopically induced in DB3. Fig. 9H corresponds to wild type GB, stage 16. DSRF is seen only in GBl . Fig. 91 corresponds to Spry* 5 homozygote. DSRF is ectopically induced in GB2. Fig. 9J corresponds to wild type GB, stage 13 and shows that DSRF is just beginning to be expressed in DBl. mAb2A12 antigen is not yet on. Fig. 9K corresponds to GB in Spry* 5 homozygote, stage 13. DSRF is induced in GB2 at the same time as GBl . Similar results were obtained for three other terminal branch markers (Terminal-2,-3, and -4). To summarize, the DSRF gene and three other marker genes (Terminal-2.-3, and -4) are induced at the ends of growing primary branches and promote terminal branching (Fig. 9F, 9H). However, in the Spry mutants, all five downstream effectors were expressed in an expanded domain that included the pre-stalk cells that later formed ectopic branches (Fig. 9B, E, G, I). Furthermore, the DSRF marker was activated at the same time as in the normal branching cells (Fig 9J,K). 3. Effect of Spry mutations on Yan expression. Another critical target of Bnl signaling is the Yan transcription factor. As in other RTK pathways (O'Neill, et al , 1994; Rebay and Rubin, 1995; Gabay, et al , 1996), activation of the Bnl pathway leads to MAPK-dependent phosphorylation and degradation of Yan, which is necessary to activate the later programs of tracheal branching (Hacohen, 1997). The effects of Spry mutations on expression of Yan are illustrated in Figs. 9L-N. In wild type, Bnl signalling leads to degradation of Yan in DBl and DB2. Fig. 9L illustrates that in the Spry^ mutant, Yan (mAb A2 8B12) is also degraded in DB3 (asterisk). Embryo was stained for DSRF (mAb2-161) to show positions of DBl and DB3. Fig. 9M is the same as Fig. 9L without DSRF channel. Fig. 9N shows that expression of the yan-lacL enhancer trap marker yan p is not changed in a Spry* 5 mutant, implying that the effect of Spry is post-transcriptional. Bars in L and N, correspond to 5 μm. To summarize, Yan is normally degraded only in the tip cells of the outgrowing primary branches. In Spry mutants, Yan was degraded in an expanded domain that coincided with the expanded domains of pnt and DSRF expression (Fig. 9L, 9M). A yan-lacL transcriptional reporter continued to be expressed normally, implying that the down regulation of Yan was a post-transcriptional event as in other RTK pathways (Fig. 9N). The above results demonstrate that Spry loss-of-function mutations lead to enhancement of all of the known downstream effectors in this Bnl pathway. 4. Effect of elevated levels of Spry. Figs. 90 and 9P demonstrate the effects of elevated levels of Spry. Fig. 90 corresponds to three DBs of wild type stage 14 embryo, showing expression of DSRF in the DBl cells (arrowheads). Fig. 9P presents a similar view of a stage 14 hsGal4/UAS-Spr 4.1 embryo heat-shocked at late stage 10 to induce Spry expression. DSRF fails to be expressed (arrowheads), and terminal branching is inhibited. When expression of Spry was induced later, at stage 13 or 14, branching was usually not inhibited, and extra branching cells were sometimes observed. In summary, an engineered gain-of-function condition in which the Spry gene product was overexpressed during embryonic stages 10 to 12 severely blocked the normal induction of downstream effectors and branching by Bnl (Figs. 90, P). The reciprocal is also true: overexpression of Bnl can overcome the opposition of Spry and induce secondary and terminal branching throughout the tracheal system (Sutherland, et al , 1996). Thus, Spry behaves genetically as a competitive antagonist of the Bnl pathway. EXAMPLE 10 Induction of Spry Expression by the Bnl Signaling Pathway The tracheal cells that express Spry are located very close to the small clusters of epidermal and mesodermal cells that express Bnl (see Sutherland, et al , 1996; schematized in Fig. 10A), and the Spry expression pattern is very similar to that of pnt and other genes induced by Bnl (Samakovlis, et al. , 1996). These observations suggested that Spry might also be induced by the Bnl pathway. To test this hypothesis, the effect of bnl pathway mutants on Spry expression was explored. The results are presented in Figs. 10 B-F in reference to Fig. 10A. Fig. 10A is a schematic showing a cluster of Sni-expressing cells (top circles) near the end of the growing DB (Sutherland, et al , 1996). Secreted Bnl (dots) causes budding (Stage 12) and outgrowth (stage 14) of the primary branch. Secreted Bnl also induces expression of genes that promote secondary and terminal branching (pnt and DSRF) in cells at the end of the primary branch (green fill) which go on to form secondary (Stage 16) and terminal branches (larva). Figs. 10B-F illustrate the effect of Bnl pathway mutants on Spry expression in the developing DB, visualized by immunostaining of the Spry9143 marker. Experimental details are as described in Example 9 above. Figs. 10B, C, and E show the results of additional staining with lumenal antisera to show branches that don't express Spry. Fig. 10B correspond to wild type, stage 12 embryo showing the two normal Spry-expressing cells DBl and 2, where Lu= lumen of the DB. Fig. 10C corresponds to M LG19 mutant. The DB does not grown out and tracheal cells fail to express Spry. Spry expression in oenocytes of the same embryo is not affected (inset). Fig. 10D corresponds to \JAS-Bnl/ + ; hsGal4/+ embryo in which Bnl was expressed ubiquitously. Spry is induced in all tracheal cells. Fig. 10E corresponds to pnt* w , stage 15 embryo. Tracheal cells fail to express Spry. Fig. 1 OF shows UAS-pntP 1.3/ + ; hsGal4/ + embryo in which the pnt PI protein was expressed ubiquitously. Spry is induced in all tracheal cells, although expression is lower outside the normal expression domain presumably because of the repressor Yan. In summary, and consistent with the initial hypothesis, in Bnl and btl mutants, Spry was not expressed or was expressed only weakly (Fig. IOC). Furthermore, when the Btl 5 receptor was activated in all tracheal cells by ubiquitous expression of Bnl , Spry was turned on at high levels throughout the tracheal system (Fig. 10D). The downstream effector pnt was also required for Spry expression (Fig 10E), and Spry expression was activated outside its normal expression domain when pnt PI protein was ubiquitously expressed (Fig 10F). Thus, Spry expression is induced by the signaling pathway that it inhibits. A schematic 10 model of a Bnl-Spry regulatory circuit is shown in Fig. 11. EXAMPLE 11 Spry Protein Expression and Localization in Mammalian Cells 15 Drosophila Spry and human Spry2 were expressed under the control of a mammalian EF-lα promoter in human 293 cells as follows. The coding regions of the Drosophila and Human Spry 2 genes were amplified by polymerase chain reaction and inserted into pEF-BOS downstream of the EF-lα promoter. The 3' primer included an in-frame epitope tag (FLAG for Drosophila Spry; HA for human 20 Spry2) for detection of the expressed proteins with antibodies against FLAG (Santa Cruz Biotechnology) or HA (Babco) epitopes. Drosophila Spry expression was also detected with an antibody (32C) raised in rabbits against full-length Spry protein. The pEF-BOS plasmids containing the Spry genes were transfected into 293 cells by standard procedures. Cells were harvested and lysed in standard lysis buffer (50 mM 25 Hepes, pH 7.4, 125 mM NaCl, 1 % Triton X-100) for 20' on ice. Alternatively cells were homogenized with a dounce homogenizer in sucrose buffer (50 mM Hepes, pH 7.4, 0.25 M sucrose); nuclei and cellular debris were spun down at 2,000 rpm and discarded; membranes (pellet) were separated from the soluble fraction (supernatant) at 100,000 rpm. Lysates or fractions were mixed with SDS sample buffer and run on 10-12% 30 polyacrylamide gels which were subsequently transferred to nitrocellulose, blocked with 5 % milk and incubated with primary and secondary antibodies and stained with ECL. Proteins were detected on Western blots of cell lysates using antibodies against the appropriate epitope tag or protein. The Western blots are shown in Figs. 12A-C. Fig. 12A shows detection of a 66kD Drosophila Spry band, recognized by anti-FLAG antibody. Fig. 35 12B corresponds to detection of hSpry2 protein at 35-40kD in 293 cells using anti-HA antibody. Fig. 12C corresponds to the 100K m pellet and supernatant of homogenized cells that express Drosophila Spry. Both proteins were efficiently expressed in this heterologous system. The molecular weights of both expressed proteins were similar to the predicted sizes of — 63 kD for Drosophila Spry and - 35 kD for hSpry2. Standard fractionation of cell homogenates revealed that the Drosophila Spry is found almost exclusively in the membrane fraction of cells. While the invention has been described with reference to specific methods and embodiments, it is appreciated that various modifications and changes may be made without departing from the invention. SEQUENCE LISTING (1) GENERAL INFORMATION (i) APPLICANT: The Board of Trustees of the Leland Stanford Junior University (ii) TITLE OF THE INVENTION: MAMMALIAN SPROUTY PROTEIN AND CODING SEQUENCE (iii) NUMBER OF SEQUENCES: 19 (iv) CORRESPONDENCE ADDRESS: (A ADDRESSEE: Dehlinger & Associates (B STREET: 350 Cambridge Avenue, Suite 250 (C CITY: Palo Alto (D STATE : CA (E COUNTRY: USA (F ZIP: 94306 (v) COMPUTER READABLE FORM: (A MEDIUM TYPE: Diskette (B COMPUTER: IBM Compatible (C OPERATING SYSTEM: DOS (D SOFTWARE : FastSEQ for Windows Version 2.0 (vi) CURRENT APPLICATION DATA: (A APPLICATION NUMBER: To be assigned (B FILING DATE: 07-NOV-1997 (C CLASSIFICATION: (vii PRIOR APPLICATION DATA: (A APPLICATION NUMBER: 60/030,232 (B: FILING DATE: 07-NOV-1996 (vii: ) ATTORNEY/AGENT INFORMATION: (A: NAME: Evans, Susan T (B REGISTRATION NUMBER: 38,443 (C REFERENCE/DOCKET NUMBER: 8600-0177.30 (ix) TELECOMMUNICATION INFORMATION: (A TELEPHONE: 650-324-0880 (B TELEFAX: 650-324-0960 (2) INFORMATION FOR SEQ ID NO : 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3254 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (vi) ORIGINAL SOURCE: (C) ISOLATE: Drosophila spry cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1323...3095 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CCGCGATTGC CGCGTTCGCT GTCTTTCCGA TTTCCTCAAA AAGCAAGCCA CTTTTTTGTA 60 TAACTACAAC ATTTTTTTTC GAAGCAACCA AATCATTTAG CAAATCGAGC AACAATAGCC 120 TGCTAAACAA AACAATTCAC TACCAGAACG CGCTAAACAA CCCGCAGATA TATATTGAAA 180 ATATATATAA AACAAGCAAT CACTTGAAAA TATTGTGTGT GGTGAAAAGT GAGTGTTTAT 240 TTTTGGGAAA TAGAAATAGA AATAGTTAAC CAAGCCAACC AACCAATCGC TTCCAATGGA 300 AATCATGTGC CTAAAAATGC AAATTGCTCG AAGAAAATCA ACAACGTCTA TTTAAAAAAC 360 AAAAAAGTCA ACTCAAGCCA ATCAAATACA AAACGTGTTG GGAAAAAGTA AAAAAAAAAA 420 ATAATATAAA AATACAGCAA ATACAAAATC AAACAACAAC AGTCTCTCGC GCACACAAAT 480 ATTTTTATAA ATCTATATAT ATGTACATAT ATAAAATTGC ATAAAAATAT TTTTTACTCA 540 AGACAACGAC GCACACACAC GCAGCACCGA GATACACAGA TACATTCGCC GCTCGCACAC 600 ACACGCACAC ATAGGCGACG ACGTGGCCCC GCTTTCGGTG TGTTAGTGTA TCTGTGTGTG 660 ATTGTGCGAC GCCAGCTTCG CTGCTCCACC AACAAAAGCA ACAACCACAA CAACACTACC 720 GCCGGTCGCC AAGTTGATTA TTATTATTTT TTTGGCCAAA AACCAAAAAC CAAACCAAAA 780 CCCAGCGAAT ATATAAAAAT ACGCGGCTGG CAAAAATAAT AACAAAATCA AACATAGTCG 840 CCGGCGTCGT TTTTGTGTTA ATTAAATTTA CTTTTGTGAA TGAAATGCGA AAGAAAGCAA 900 AGCGAAAAAT CACCTTTAAT AAATGCTAAA TTAAAACCAG CAGTCGCGAT CGCGAGTAAG 960 CATCTGAAGA ACCCCCCTCT CCAAATCGCC TTTGGATTAC ACTCAAAAGA AACGAATTCA 1020 TCATTTTGGA TACTTTTCGA AAAATAAGGA TTACACAACA CTTTCAACTC ACATCTACGG 1080 TGATTAATTA CGGAATTTGT ACCACGGATT GCTTTTGAAA ATCAATAAAG CAATCGCAGC 1140 TGTCTGAATC TGCAAAAGGA TGAAGGCAAA TCAAGCTGAG TCCGGGCGCA GTAACTACGA 1200 TCGACGGCAT TGAGGATCTC GGATCTCGAG GTGGAGGAGC GATCTCGATC TCGAGGTGGA 1260 GCGAGGAGCG GAGGAGGAGT GGAGGAGTGC AGCTGGGGGA GGAGTCCTGG TTACAACACT 1320 AC ATG GAT CGC AGA AAT GGC GGC GAT CCC TTG GCG CCA CCC CGG CCC 1367 Met Asp Arg Arg Asn Gly Gly Asp Pro Leu Ala Pro Pro Arg Pro 1 5 10 15 CCG AAG TTA TTA CCG CGC GTG CAT CGA CCA AGG GCG CCG GAG CCG ACG 1415 Pro Lys Leu Leu Pro Arg Val His Arg Pro Arg Ala Pro Glu Pro Thr 20 25 30 TTA AGT GGT GTC GAC CAT ACC GCA GGA GCA ACT GCA TCC GCA CTA GCA 1463 Leu Ser Gly Val Asp His Thr Ala Gly Ala Thr Ala Ser Ala Leu Ala 35 40 45 TCA GGA GCA TCA TCT GCA GCA CCC GTA GCA ATC CAT AAC AAC AAT TCA 1511 Ser Gly Ala Ser Ser Ala Ala Pro Val Ala lie His Asn Asn Asn Ser 50 55 60 CAG CAG CAA CTT AGT ATT AGC GCC GCC GCG AGC AAC AAC AAT ACG ATA 1559 Gin Gin Gin Leu Ser lie Ser Ala Ala Ala Ser Asn Asn Asn Thr lie 65 70 75 TCG ATA ATA CCC GCA TCG CCG GAC TTC GAC GAC TAC CAG ATC CAC CAC 1607 Ser lie lie Pro Ala Ser Pro Asp Phe Asp Asp Tyr Gin lie His His 80 85 90 95 CTG ACC TTC CTG CCC CAG CGA CCA AGC AGT CTG AGC CGG AAC AGC AGT 1655 Leu Thr Phe Leu Pro Gin Arg Pro Ser Ser Leu Ser Arg Asn Ser Ser 100 105 110 ACG GCG TCA TCG ACT ACG GCG ACG GGC ATT AGT GTC TCC GGT TCG GGA 1703 Thr Ala Ser Ser Thr Thr Ala Thr Gly lie Ser Val Ser Gly Ser Gly 115 120 125 TCT GTT TCG GGT TCG TCG TCC AGC TTC ACG AGA CGT CGA CCG CCG GCA 1751 Ser Val Ser Gly Ser Ser Ser Ser Phe Thr Arg Arg Arg Pro Pro Ala 130 135 140 CCT GTA CCG CTG AAC AAC AGC ATC AGC AAC AAC AAC AAC AAC AGC ATC 1799 Pro Val Pro Leu Asn Asn Ser lie Ser Asn Asn Asn Asn Asn Ser lie 145 150 155 AAC AAC AAC TTC CTT AGT CAT TTC CAA AGC GCT GAG CCG GCG AGC AAC 1847 Asn Asn Asn Phe Leu Ser His Phe Gin Ser Ala Glu Pro Ala Ser Asn 160 165 170 175 GCT CTG GGC CAG CCG CCC GCC TCC CCC GTC ACG CTG GCG CAA CCG CGA 1895 Ala Leu Gly Gin Pro Pro Ala Ser Pro Val Thr Leu Ala Gin Pro Arg 180 185 190 CCC GAA TCC GAA AGG CTA ACC AAT GAG TAT GTG GAC ACG CCG CTG CAA 1943 Pro Glu Ser Glu Arg Leu Thr Asn Glu Tyr Val Asp Thr Pro Leu Gin 195 200 205 CAT GCG ACG CGC TCG CAG CAT CCG GCT GGC CAG CAG GAT AAT GGC CAG 1991 His Ala Thr Arg Ser Gin His Pro Ala Gly Gin Gin Asp Asn Gly Gin 210 215 220 ACG ACC ACC CAC CAC CTG TTG CTG CTG CCC CAG CGG AAT CAG CAC CTG 2039 Thr Thr Thr His His Leu Leu Leu Leu Pro Gin Arg Asn Gin His Leu 225 230 235 CAC CTG CAA CAA CAC CAG CAG CAC CTG CAA CAG CAA CAG CAG CAG CAG 2087 His Leu Gin Gin His Gin Gin His Leu Gin Gin Gin Gin Gin Gin Gin 240 245 250 255 CAA CAG CAG CAG CAG CAG CAG CAG CAG CAT CTG CAG CAC CAG CAA AAC 2135 Gin Gin Gin Gin Gin Gin Gin Gin Gin His Leu Gin His Gin Gin Asn 260 265 270 CAG CAA CAT GCG CGA CTG GCG ACG ACG ACG CAG GCG ACG TCC GTT GGA 2183 Gin Gin His Ala Arg Leu Ala Thr Thr Thr Gin Ala Thr Ser Val Gly 275 280 285 AGC GAC CAC ACC GAT GGC TTA CTA CAT TCG CAC CTG CAA AAT AGC ACC 2231 Ser Asp His Thr Asp Gly Leu Leu His Ser His Leu Gin Asn Ser Thr 290 295 300 ACT AAA CCA CCC GCC TCG AAG CAG CCG GCA CTG CCC AGA CTG GGA ATG 2279 Thr Lys Pro Pro Ala Ser Lys Gin Pro Ala Leu Pro Arg Leu Gly Met 305 310 315 GGC CTG GGA TTG GGA TTG GGT CTC GGT CTG AAC CAG CCC ATC ATC ACC 2327 Gly Leu Gly Leu Gly Leu Gly Leu Gly Leu Asn Gin Pro lie lie Thr 320 325 330 335 AAG CAG CCG ACA CCC GCC ACG CAA AAG GAG CGC ATG CAC GCG CTG GAG 2375 Lys Gin Pro Thr Pro Ala Thr Gin Lys Glu Arg Met His Ala Leu Glu 340 345 350 GAG CTG CTG CAA CCA GGC GGA GCC GGC GGC AAC GGA GGA CCC CTG GTG 2423 Glu Leu Leu Gin Pro Gly Gly Ala Gly Gly Asn Gly Gly Pro Leu Val 355 360 365 ATG GCC GGC GAT CCC AGC CTG CTG AAT CCC ATC GTC TGT CCG CGA TGC 2471 Met Ala Gly Asp Pro Ser Leu Leu Asn Pro lie Val Cys Pro Arg Cys 370 375 380 GGT CGC TGT CGC TGC GAG CAG TGC CAG AGC CCC AGG CCA CTG CCC CAG 2519 Gly Arg Cys Arg Cys Glu Gin Cys Gin Ser Pro Arg Pro Leu Pro Gin 385 390 395 ACG TGG GTG TGC AAC AAG ACG TGT CTG TGC AGC GCG GAG TCG GTT ATC 2567 Thr Trp Val Cys Asn Lys Thr Cys Leu Cys Ser Ala Glu Ser Val lie 400 405 410 415 GAC TAT GCC TCC TGC TTG TGC TGC GCC AAG GCT CTG TTC TAT CAC TGC 2615 Asp Tyr Ala Ser Cys Leu Cys Cys Ala Lys Ala Leu Phe Tyr His Cys 420 425 430 GCC CGG GAC AAC GAC CTG GAC TGC GAT GAT GGC AAC GGC ACA CCC TGC 2663 Ala Arg Asp Asn Asp Leu Asp Cys Asp Asp Gly Asn Gly Thr Pro Cys 435 440 445 GTG GAT AAT CCC TGC TCC TGC GGC CCC TAC AAG CGC ACC CAG AGA TGG 2711 Val Asp Asn Pro Cys Ser Cys Gly Pro Tyr Lys Arg Thr Gin Arg Trp 450 455 460 GGC TGG CTG GGA GCA CTG TCG ATC TTC CTG CCC TGC CTG TGG TTC TAC 2759 Gly Trp Leu Gly Ala Leu Ser lie Phe Leu Pro Cys Leu Trp Phe Tyr 465 470 475 TGG CCC ATG CGG GGC TGC ATG AAG CTG TGC GAG AAA TGC TAC GGC AGG 2807 Trp Pro Met Arg Gly Cys Met Lys Leu Cys Glu Lys Cys Tyr Gly Arg 480 485 490 495 TTC GCC GGT CGG GGA TGC CGC TGT CAG GGC ATC GGC GGA GGA GGG GCA 2855 Phe Ala Gly Arg Gly Cys Arg Cys Gin Gly He Gly Gly Gly Gly Ala 500 505 510 GGT TCC GGA GGC GGA GTC GGT AGC ATT GGA TCC ACC AGC AGC ATG CTG 2903 Gly Ser Gly Gly Gly Val Gly Ser He Gly Ser Thr Ser Ser Met Leu 515 520 525 CCC ATA GTG CCT CTT GGG GTG AAT GGC AGT GGG CTG GGT GGC GGC GTG 2951 Pro He Val Pro Leu Gly Val Asn Gly Ser Gly Leu Gly Gly Gly Val 530 535 ■ 540 AGC CTC TCC GGC GGC GTG ACG GAT GGT GGA CTC AAC CAA GCC AAT GGC 2999 Ser Leu Ser Gly Gly Val Thr Asp Gly Gly Leu Asn Gin Ala Asn Gly 545 550 555 AAG GCC ATG GAT CAT GGA TGC AGT GCC GCC AGG AGC ATA CTG CGA AAG 3047 Lys Ala Met Asp His Gly Cys Ser Ala Ala Arg Ser He Leu Arg Lys 560 565 570 575 GGT GAC CTC ACC CCG GAG AAG CGG CTC CTG GAC TCC AGT CCC GAC TAC T 3096 Gly Asp Leu Thr Pro Glu Lys Arg Leu Leu Asp Ser Ser Pro Asp Tyr 580 585 590 AAGGGTCCAT TCCATGTGTC CGGTTTTTTA CCCGAGCAAA AAGCCTAAGG CACAAATGGG 3156 ATGCTGGATC GTGGACATAT ACACCCATAT ATATACGGAA AATATTTAAT ATATGATTTA 3216 AAAGGATATA TAAAAAAAGA GGAAAAAAAA AAAAAAGG 3254 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 591 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : Met Asp Arg Arg Asn Gly Gly Asp Pro Leu Ala Pro Pro Arg Pro Pro 1 5 10 15 Lys Leu Leu Pro Arg Val His Arg Pro Arg Ala Pro Glu Pro Thr Leu 20 25 30 Ser Gly Val Asp His Thr Ala Gly Ala Thr Ala Ser Ala Leu Ala Ser 35 40 45 Gly Ala Ser Ser Ala Ala Pro Val Ala He His Asn Asn Asn Ser Gin 50 55 60 Gin Gin Leu Ser He Ser Ala Ala Ala Ser Asn Asn Asn Thr He Ser 65 70 75 80 He He Pro Ala Ser Pro Asp Phe Asp Asp Tyr Gin He His His Leu 85 90 95 Thr Phe Leu Pro Gin Arg Pro Ser Ser Leu Ser Arg Asn Ser Ser Thr 100 105 110 Ala Ser Ser Thr Thr Ala Thr Gly He Ser Val Ser Gly Ser Gly Ser 115 120 125 Val Ser Gly Ser Ser Ser Ser Phe Thr Arg Arg Arg Pro Pro Ala Pro 130 135 140 Val Pro Leu Asn Asn Ser He Ser Asn Asn Asn Asn Asn Ser He Asn 145 150 155 160 Asn Asn Phe Leu Ser His Phe Gin Ser Ala Glu Pro Ala Ser Asn Ala 165 170 175 Leu Gly Gin Pro Pro Ala Ser Pro Val Thr Leu Ala Gin Pro Arg Pro 180 185 190 Glu Ser Glu Arg Leu Thr Asn Glu Tyr Val Asp Thr Pro Leu Gin His 195 200 205 Ala Thr Arg Ser Gin His Pro Ala Gly Gin Gin Asp Asn Gly Gin Thr 210 215 220 Thr Thr His His Leu Leu Leu Leu Pro Gin Arg Asn Gin His Leu His 225 230 235 240 Leu Gin Gin His Gin Gin His Leu Gin Gin Gin Gin Gin Gin Gin Gin 245 250 255 Gin Gin Gin Gin Gin Gin Gin Gin His Leu Gin His Gin Gin Asn Gin 260 265 270 Gin His Ala Arg Leu Ala Thr Thr Thr Gin Ala Thr Ser Val Gly Ser 275 280 285 Asp His Thr Asp Gly Leu Leu His Ser His Leu Gin Asn Ser Thr Thr 290 295 300 Lys Pro Pro Ala Ser Lys Gin Pro Ala Leu Pro Arg Leu Gly Met Gly 305 310 315 320 Leu Gly Leu Gly Leu Gly Leu Gly Leu Asn Gin Pro He He Thr Lys 325 330 335 Gin Pro Thr Pro Ala Thr Gin Lys Glu Arg Met His Ala Leu Glu Glu 340 345 350 Leu Leu Gin Pro Gly Gly Ala Gly Gly Asn Gly Gly Pro Leu Val Met 355 360 365 Ala Gly Asp Pro Ser Leu Leu Asn Pro He Val Cys Pro Arg Cys Gly 370 375 380 Arg Cys Arg Cys Glu Gin Cys Gin Ser Pro Arg Pro Leu Pro Gin Thr 385 390 395 400 Trp Val Cys Asn Lys Thr Cys Leu Cys Ser Ala Glu Ser Val He Asp 405 410 415 Tyr Ala Ser Cys Leu Cys Cys Ala Lys Ala Leu Phe Tyr His Cys Ala 420 425 430 Arg Asp Asn Asp Leu Asp Cys Asp Asp Gly Asn Gly Thr Pro Cys Val 435 440 445 Asp Asn Pro Cys Ser Cys Gly Pro Tyr Lys Arg Thr Gin Arg Trp Gly 450 455 460 Trp Leu Gly Ala Leu Ser He Phe Leu Pro Cys Leu Trp Phe Tyr Trp 465 470 475 480 Pro Met Arg Gly Cys Met Lys Leu Cys Glu Lys Cys Tyr Gly Arg Phe 485 490 495 Ala Gly Arg Gly Cys Arg Cys Gin Gly He Gly Gly Gly Gly Ala Gly 500 505 510 Ser Gly Gly Gly Val Gly Ser He Gly Ser Thr Ser Ser Met Leu Pro 515 520 525 He Val Pro Leu Gly Val Asn Gly Ser Gly Leu Gly Gly Gly Val Ser 530 535 540 Leu Ser Gly Gly Val Thr Asp Gly Gly Leu Asn Gin Ala Asn Gly Lys 545 550 555 560 Ala Met Asp His Gly Cys Ser Ala Ala Arg Ser He Leu Arg Lys Gly 565 570 575 Asp Leu Thr Pro Glu Lys Arg Leu Leu Asp Ser Ser Pro Asp Tyr 580 585 590 (2) INFORMATION FOR SEQ ID NO : 3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...372 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3 : TGT CCG CGA TGC GGT CGC TGT CGC TGC GAG CAG TGC CAG AGC CCC AGG 48 Cys Pro Arg Cys Gly Arg Cys Arg Cys Glu Gin Cys Gin Ser Pro Arg 1 5 10 15 CCA CTG CCC CAG ACG TGG GTG TGC AAC AAG ACG TGT CTG TGC AGC GCG 96 Pro Leu Pro Gin Thr Trp Val Cys Asn Lys Thr Cys Leu Cys Ser Ala 20 25 30 GAG TCG GTT ATC GAC TAT GCC TCC TGC TTG TGC TGC GCC AAG GCT CTG 144 Glu Ser Val He Asp Tyr Ala Ser Cys Leu Cys Cys Ala Lys Ala Leu 35 40 45 TTC TAT CAC TGC GCC CGG GAC AAC GAC CTG GAC TGC GAT GAT GGC AAC 192 Phe Tyr His Cys Ala Arg Asp Asn Asp Leu Asp Cys Asp Asp Gly Asn 50 55 60 GGC ACA CCC TGC GTG GAT AAT CCC TGC TCC TGC GGC CCC TAC AAG CGC 240 Gly Thr Pro Cys Val Asp Asn Pro Cys Ser Cys Gly Pro Tyr Lys Arg 65 70 75 80 ACC CAG AGA TGG GGC TGG CTG GGA GCA CTG TCG ATC TTC CTG CCC TGC 288 Thr Gin Arg Trp Gly Trp Leu Gly Ala Leu Ser He Phe Leu Pro Cys 85 90 95 CTG TGG TTC TAC TGG CCC ATG CGG GGC TGC ATG AAG CTG TGC GAG AAA 336 Leu Trp Phe Tyr Trp Pro Met Arg Gly Cys Met Lys Leu Cys Glu Lys 100 105 110 TGC TAC GGC AGG TTC GCC GGT CGG GGA TGC CGC TGT 372 Cys Tyr Gly Arg Phe Ala Gly Arg Gly Cys Arg Cys 115 120 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 124 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (C) ISOLATE: d-spry cysteine-rich protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Cys Pro Arg Cys Gly Arg Cys Arg Cys Glu Gin Cys Gin Ser Pro Arg 1 5 10 15 Pro Leu Pro Gin Thr Trp Val Cys Asn Lys Thr Cys Leu Cys Ser Ala 20 25 30 Glu Ser Val He Asp Tyr Ala Ser Cys Leu Cys Cys Ala Lys Ala Leu 35 40 45 Phe Tyr His Cys Ala Arg Asp Asn Asp Leu Asp Cys Asp Asp Gly Asn 50 55 60 Gly Thr Pro Cys Val Asp Asn Pro Cys Ser Cys Gly Pro Tyr Lys Arg 65 70 75 80 Thr Gin Arg Trp Gly Trp Leu Gly Ala Leu Ser He Phe Leu Pro Cys 85 90 95 Leu Trp Phe Tyr Trp Pro Met Arg Gly Cys Met Lys Leu Cys Glu Lys 100 105 110 Cys Tyr Gly Arg Phe Ala Gly Arg Gly Cys Arg Cys 115 120 (2) INFORMATION FOR SEQ ID NO: 5; (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1603 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spryl cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...420 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: TGT GAA CAG TGT GGG AAG TGC AAG TGT GGA GAA TGC ACT GCT CCC AGG 48 Cys Glu Gin Cys Gly Lys Cys Lys Cys Gly Glu Cys Thr Ala Pro Arg 1 5 10 15 ACC CTA CCA TCC TGT TTG GCC TGT AAC CGG CAG TGC CTT TGC TCT GCT 96 Thr Leu Pro Ser Cys Leu Ala Cys Asn Arg Gin Cys Leu Cys Ser Ala 20 25 30 GAG AGC ATG GTG GAA TAT GGA ACC TGC ATG TGC TTA GTC AAG GGC ATC 144 Glu Ser Met Val Glu Tyr Gly Thr Cys Met Cys Leu Val Lys Gly He 35 40 45 TTC TAC CAC TGC TCC AAT GAC GAC GAA GGG GAT TCC TAT TCA GAT AAT 192 Phe Tyr His Cys Ser Asn Asp Asp Glu Gly Asp Ser Tyr Ser Asp Asn 50 55 60 CCT TGC TCC TGT TCA CAA TCA CAC TGC TGC TCT AGA TAC CTG TGT ATG 240 Pro Cys Ser Cys Ser Gin Ser His Cys Cys Ser Arg Tyr Leu Cys Met 65 70 75 80 GGA GCC ATG TCT TTA TTT TTA CCT TGC TTA CTC TGT TAT CCT CCT GCT 288 Gly Ala Met Ser Leu Phe Leu Pro Cys Leu Leu Cys Tyr Pro Pro Ala 85 90 95 AAA GGA TGC CTG AAG CTG TCA GGA GGT GTT ATG ACT GGA TCC ATC GCC 336 Lys Gly Cys Leu Lys Leu Ser Gly Gly Val Met Thr Gly Ser He Ala 100 105 110 CAG GGT GCA GAT GTA AGA ACT CCA ACA CTG TCT ATT GTA AGC TGG AGA 384 Gin Gly Ala Asp Val Arg Thr Pro Thr Leu Ser He Val Ser Trp Arg 115 120 125 GCT GCC CCT CCC GGG GTC AGG GTA AAC CAT CAT GAT TTTTGGAGGT GGGTTG 436 Ala Ala Pro Pro Gly Val Arg Val Asn His His Asp 130 135 140 TACCTCCTGA ACTTTTAGCT TTCAAGTTGT GGCTGTTTTT TGTTTTGTTT TGTTTGTTTT 496 CTTTAAATTT TCCGTTCCCT CCTTCCCCTG TTGCCAAGGT CTAACTCATG GATTTTTCTC 556 TTTCCTCATG GATGATCTTC AGCAAGAGTG GACTGGGAAG CTGCACCTGG CTCCCACTTT 616 CAACAAGAGC CTCTGCCATC CACTTGAGGG TATTGAGAGC CAGTGGGCTT TTGTGTACCT 676 TTTTGTTCTG CAAGCAACTT TCTAAAGTTG TGTACATGAA CATACACCCA CATCCAGAAC 736 AGTGATTTAG AGTTGTTTTG ATTGGGTACC GTGGGAGCAG GGAAATTGGT TTTTTAAAAA 796 GCAACTGTTT AATTGCTTAA ATAAGCTATG TATTAAATCT GTCTCCAGTT AGGGCTATCT 856 TCCTAGCATA GGCCCCTTAA GTAGCATGGG GGAATTTTGT ATAACGTAAA AATTTCCTTT 916 AACCACTGCC CTCTCCTTCT TTTCCTTCAA GGTTTTTCCC CCTCAGTTTG TTGTTGTCTT 976 ATTGGAGATG CCAAGTGATT TTTTCTTTTA TGTAATTTTA GATTGCCTAC AATGTAAATT 1036 TCACATTGGA GATAATATTG GTTGGACCTC GCCCATCTTC ACTTAGCCTT CGTATTTGTG 1096 AAGGATTCAG CCACCTTCCT TCTTCACCCC ATGCTTCTCA CCAAAATTTT GTTGTCATTG 1156 AGGGCACTTG GATAACTCAA GTTGATATTT ATAGCTGATC AATCTATATG TGTCACAGAA 1216 CTATGCTGCC TAAAGTGATC TTGGCTCCTT AATGGTCCTT TTGGCCCCTT GGATAGTTAA 1276 CAGCTGAGTA ATTCTAATCT CTTCTGTGTT TTCCTTGCCT TAACCACAAA TTGTGGTGCT 1336 TTTTGTATAT TTTATGT TA AATCACAAAG TTGAATTCTG ACTATTTTTA AGACAAAAGT 1396 CTGTTAAACT TTTTTATTGT AAAGAATATT TATTATGCGA ATCTCTATTA TTTTATGGTA 1456 TTTATTGCAA AAGACTGTTG AAATGTACTC ATGTTTGAAT ATAACAAAAT ATCAATACTT 1516 AACGGAAAAT AAGGTGACAC GAAGAAAGTA CAT TGTTAA CTATAATGCA GAAAATATAT 1576 TAATTAATGA AAAAAAAAAA AAAAAAA 1603 (2) INFORMATION FOR SEQ ID NO : 6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 117 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spryl cysteine-rich protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : Cys Glu Gin Cys Gly Lys Cys Lys Cys Gly Glu Cys Thr Ala Pro Arg 1 5 10 15 Thr Leu Pro Ser Cys Leu Ala Cys Asn Arg Gin Cys Leu Cys Ser Ala 20 25 30 Glu Ser Met Val Glu Tyr Gly Thr Cys Met Cys Leu Val Lys Gly He 35 40 45 Phe Tyr His Cys Ser Asn Asp Asp Glu Gly Asp Ser Tyr Ser Asp Asn 50 55 60 Pro Cys Ser Cys Ser Gin Ser His Cys Cys Ser Arg Tyr Leu Cys Met 65 70 75 80 Gly Ala Met Ser Leu Phe Leu Pro Cys Leu Leu Cys Tyr Pro Pro Ala 85 90 95 Lys Gly Cys Leu Lys Leu Xaa Arg Arg Cys Tyr Asp Trp He His Arg 100 105 110 Pro Gly Cys Arg Cys 115 (2) INFORMATION FOR SEQ ID NO : 7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2135 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spry2 cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 391...1335 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:- GGCACGAGGG TAAGGCCGTT TTCTTTTCCC ATTCGCTCAT CTGCCAGGAA AAGGGACTTG 60 CCGTTGGCGC TTCGGCCTCT TGTTCATTGA GAAAAAAGAG GAAATACTCC GCGTGCGCTT 120 GTAGAAGGGG AGTCGTCTCC AGCTCCGAAC CCCGGAGTGT TCATCAGCGG GGAATCTGGC 180 TCCGAATTCT CTTTTTTTCT CCCGCCGATT GCTCGGAAGT TGGTCTAAAG CAGAGGTTGG 240 AAAGAAAGGA AAAAAGTTTG CATCGAGACT GGATTTATTT GCACATCGCA GAAAGAAGAG 300 AATCCAAGGG AGAGGGGTTG GTGCAAAGCC GCGATCACGG AGTTCAGATG TGTTCTAAGC 360 CTGCTGGAGT GACCACACTT CCAAGACCTG ATG GAG GCC AGA GCT CAG AGT GGC 414 Met Glu Ala Arg Ala Gin Ser Gly 1 5 AAC GGG TCG CAG CCC TTG CTG CAG ACG CCC CGT GAC GGT GGC AGA CAG 462 Asn Gly Ser Gin Pro Leu Leu Gin Thr Pro Arg Asp Gly Gly Arg Gin 10 15 20 CGT GGG GAG CCC GAC CCC AGA GAC GCC CTC ACC CAG CAG GTA CAT GTC 510 Arg Gly Glu Pro Asp Pro Arg Asp Ala Leu Thr Gin Gin Val His Val 25 30 35 40 TTG TCT CTG GAT CAG ATC AGA GCC ATC CGA AAC ACC AAT GAG TAC ACA 558 Leu Ser Leu Asp Gin He Arg Ala He Arg Asn Thr Asn Glu Tyr Thr 45 50 55 GAG GGG CCT ACT GTC GTC CCA AGA CCT GGG CTC AAG CCT GCT CCT CGC 606 Glu Gly Pro Thr Val Val Pro Arg Pro Gly Leu Lys Pro Ala Pro Arg 60 65 70 CCC TCC ACT CAG CAC AAA CAC GAG AGA CTC CAC GGT CTG CCT GAG CAC 654 Pro Ser Thr Gin His Lys His Glu Arg Leu His Gly Leu Pro Glu His 75 80 85 CGC CAG CCT CCT AGG CTC CAG CAC TCG CAG GTC CAT TCT TCT GCA CGA 702 Arg Gin Pro Pro Arg Leu Gin His Ser Gin Val His Ser Ser Ala Arg 90 95 100 GCC CCT CTG TCC AGA TCC ATA AGC ACG GTC AGC TCA GGG TCG CGG AGC 750 Ala Pro Leu Ser Arg Ser He Ser Thr Val Ser Ser Gly Ser Arg Ser 105 110 115 120 AGT ACG AGG ACA AGT ACC AGC AGC AGC TCC TCT GAA CAG AGA CTG CTA 798 Ser Thr Arg Thr Ser Thr Ser Ser Ser Ser Ser Glu Gin Arg Leu Leu 125 130 135 GGA TCA TCC TTC TCC TCC GGG CCT GTT GCT GAT GGC ATA ATC CGG GTG 846 Gly Ser Ser Phe Ser Ser Gly Pro Val Ala Asp Gly He He Arg Val 140 145 150 CAA CCC AAA TCT GAG CTC AAG CCA GGT GAG CTT AAG CCA CTG AGC AAG 894 Gin Pro Lys Ser Glu Leu Lys Pro Gly Glu Leu Lys Pro Leu Ser Lys 155 160 165 GAA GAT TTG GGC CTG CAC GCC TAC AGG TGT GAG GAC TGT GGC AAG -TGC 942 Glu Asp Leu Gly Leu His Ala Tyr Arg Cys Glu Asp Cys Gly Lys Cys 170 175 180 AAA TGT AAG GAG TGC ACC TAC CCA AGG CCT CTG CCA TCA GAC TGG ATC 990 Lys Cys Lys Glu Cys Thr Tyr Pro Arg Pro Leu Pro Ser Asp Trp He 185 190 195 200 TGC GAC AAG CAG TGC CTT TGC TCG GCC CAG AAC GTG ATT GAC TAT GGG 1038 Cys Asp Lys Gin Cys Leu Cys Ser Ala Gin Asn Val He Asp Tyr Gly 205 210 215 ACT TGT GTA TGC TGT GTG AAA GGT CTC TTC TAT CAC TGT TCT AAT GAT 1086 Thr Cys Val Cys Cys Val Lys Gly Leu Phe Tyr His Cys Ser Asn Asp 220 225 230 GAT GAG GAC AAC TGT GCT GAC AAC CCA TGT TCT TGC AGC CAG TCT CAC 1134 Asp Glu Asp Asn Cys Ala Asp Asn Pro Cys Ser Cys Ser Gin Ser His 235 240 245 TGT TGT ACA CGA TGG TCA GCC ATG GGT GTC ATG TCC CTC TTT TTG CCT 1182 Cys Cys Thr Arg Trp Ser Ala Met Gly Val Met Ser Leu Phe Leu Pro 250 255 260 TGT TTA TGG TGT TAC CTT CCA GCC AAG GGT TGC CTT AAA TTG TGC CAG 1230 Cys Leu Trp Cys Tyr Leu Pro Ala Lys Gly Cys Leu Lys Leu Cys Gin 265 270 275 280 GGG TGT TAT GAC CGG GTT AAC AGG CCT GGT TGC CGC TGT AAA AAC TCA 1278 Gly Cys Tyr Asp Arg Val Asn Arg Pro Gly Cys Arg Cys Lys Asn Ser 285 290 295 AAC ACA GTT TGC TGC AAA GTT CCC ACT GTC CCC CCT AGG AAC TTT GAA 1326 Asn Thr Val Cys Cys Lys Val Pro Thr Val Pro Pro Arg Asn Phe Glu 300 305 310 AAA CCA ACA TAGCATCATT AATCAGGAAT ATTACAGTAA TGAGGATTTT TTCTTTCTT 1384 Lys Pro Thr 315 TTTTTAATAC ACATATGCAA CCAACTAAAC AGTTATAATC TTGGCACTGT TAATCGAAAG 1444 TTGGGATAGT CTTTGCTGTT TGCGGTGAAA TGCTTTTTGT CCATGTGCCG TTTTAACTGA 1504 TATGCTTGTT AGAACTCAGC TAATGGAGCT CAAAGTATGA GATACAGAAC TTGGTGACCC 1564 ATGTATTGCA TAAGCTAAAG CAACACAGAC ACTCCTAGGC AAAGTTTTTG TTTGTGAATA 1624 GTACTTGCAA AACTTGTAAA TTAGCAGATG ACTTTTTTCC ATTGTTTTCT CCAGAGAGAA 1684 TGTGCTATAT TTTTGTATAT ACAATAATAT TTGCAACTGT GAAAAACAAG TTGTGCCATA 1744 CTACATGGCA CAGACACAAA ATATTATACT AATATGTTGT ACATTCGGAA GAATGTGAAT 1804 CAATCAGTAT GTTTTTAGAT TGTATTTTGC CTTACAGAAA GCCTTTATTG TAAGACTCTG 1864 ATTTCCCTTT GGACTTCATG TATATTGTAC AGTTACAGTA AAATTCAACC TTTATTTTCT 1924 AATTTTTTCA ACATATTGTT TAGTGTAAAG AATATTTATT TGAAGTTTTA TTATTTTATA 1984 AAAAAGAATA TTTATTTTAA GAGGCATCTT ACAAATTTTG CCCCTTTTAT GAGGATGTGA 2044 TAGTTGCTGC AAATGAGGGG TTACAGATGC ATATGTCCAA TATAAAATAG AAAATATATT 2104 AACGTTTGAA ATTAAAAAAA AAAAAAAAAA A 2135 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 315 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spry2 protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Glu Ala Arg Ala Gin Ser Gly Asn Gly Ser Gin Pro Leu Leu Gin 1 5 10 15 Thr Pro Arg Asp Gly Gly Arg Gin Arg Gly Glu Pro Asp Pro Arg Asp 20 25 30 Ala Leu Thr Gin Gin Val His Val Leu Ser Leu Asp Gin He Arg Ala 35 40 45 He Arg Asn Thr Asn Glu Tyr Thr Glu Gly Pro Thr Val Val Pro Arg 50 55 60 Pro Gly Leu Lys Pro Ala Pro Arg Pro Ser Thr Gin His Lys His Glu 65 70 75 80 Arg Leu His Gly Leu Pro Glu His Arg Gin Pro Pro Arg Leu Gin His 85 90 95 Ser Gin Val His Ser Ser Ala Arg Ala Pro Leu Ser Arg Ser He Ser 100 105 110 Thr Val Ser Ser Gly Ser Arg Ser Ser Thr Arg Thr Ser Thr Ser Ser 115 120 125 Ser Ser Ser Glu Gin Arg Leu Leu Gly Ser Ser Phe Ser Ser Gly Pro 130 135 140 Val Ala Asp Gly He He Arg Val Gin Pro Lys Ser Glu Leu Lys Pro 145 150 155 160 Gly Glu Leu Lys Pro Leu Ser Lys Glu Asp Leu Gly Leu His Ala Tyr 165 170 175 Arg Cys Glu Asp Cys Gly Lys Cys Lys Cys Lys Glu Cys Thr Tyr Pro 180 185 190 Arg Pro Leu Pro Ser Asp Trp He Cys Asp Lys Gin Cys Leu Cys Ser 195 200 205 Ala Gin Asn Val He Asp Tyr Gly Thr Cys Val Cys Cys Val Lys Gly 210 215 220 Leu Phe Tyr His Cys Ser Asn Asp Asp Glu Asp Asn Cys Ala Asp Asn 225 230 235 240 Pro Cys Ser Cys Ser Gin Ser His Cys Cys Thr Arg Trp Ser Ala Met 245 250 255 Gly Val Met Ser Leu Phe Leu Pro Cys Leu Trp Cys Tyr Leu Pro Ala 260 265 270 Lys Gly Cys Leu Lys Leu Cys Gin Gly Cys Tyr Asp Arg Val Asn Arg 275 280 285 Pro Gly Cys Arg Cys Lys Asn Ser Asn Thr Val Cys Cys Lys Val Pro 290 295 300 Thr Val Pro Pro Arg Asn Phe Glu Lys Pro Thr 305 310 315 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 116 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spry2 cysteine-rich region (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Cys Glu Asp Cys Gly Lys Cys Lys Cys Lys Glu Cys Thr Tyr Pro Arg 1 5 10 15 Pro Leu Pro Ser Asp Trp He Cys Asp Lys Gin Cys Leu Cys Ser Ala 20 25 30 Gin Asn Val He Asp Tyr Gly Thr Cys Val Cys Cys Val Lys Gly Leu 35 40 45 Phe Tyr His Cys Ser Asn Asp Asp Glu Asp Asn Cys Ala Asp Asn Pro 50 55 60 Cys Ser Cys Ser Gin Ser His Cys Cys Thr Arg Trp Ser Ala Met Gly 65 70 75 80 Val Met Ser Leu Phe Leu Pro Cys Leu Trp Cys Tyr Leu Pro Ala Lys 85 90 95 Gly Cys Leu Lys Leu Cys Gin Gly Cys Tyr Asp Arg Val Asn Arg Pro 100 105 110 Gly Cys Arg Cys 115 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spry3 (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...300 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: CCC CTG CCT CTT GAT CAA AGG CTC CTG GCC AGC ATT ACA CCC TCA CCT 48 Pro Leu Pro Leu Asp Gin Arg Leu Leu Ala Ser He Thr Pro Ser Pro 1 5 10 15 TCA GGC CAA TCC ATC ATC CGA ACC CAA CCT GGA GCA GGG GTC CAC CCA 96 Ser Gly Gin Ser He He Arg Thr Gin Pro Gly Ala Gly Val His Pro 20 25 30 AAG GCT GAT GGT GCT CTG AAG GGA GAA GCT GAG CAA TCT GCA GGG CAC 144 Lys Ala Asp Gly Ala Leu Lys Gly Glu Ala Glu Gin Ser Ala Gly His 35 40 45 CCT AGT GAG CAC CTC TTC ATC TGT GAG GAA TGT GGG CGC TGC AAG TGC 192 5 Pro Ser Glu His Leu Phe He Cys Glu Glu Cys Gly Arg Cys Lys Cys 50 55 60 GTC CCC TGC ACA GCA GCT CGC CCT CTC CCC TCC TGC TGG CTG TGC AAC 240 Val Pro Cys Thr Ala Ala Arg Pro Leu Pro Ser Cys Trp Leu Cys Asn 10 65 70 75 80 CAG CGC TGC CTT TGC TCT GCT GAG AGC CTC CTC GAT TAT GGC ACT TGT 288 Gin Arg Cys Leu Cys Ser Ala Glu Ser Leu Leu Asp Tyr Gly Thr Cys 85 90 95 15 CTC TGC TGT GTC 300 Leu Cys Cys Val 20 100 (2) INFORMATION FOR SEQ ID NO: 11: 25 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 100 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 30 (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spry3 cysteine-rich region (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: 35 Pro Leu Pro Leu Asp Gin Arg Leu Leu Ala Ser He Thr Pro Ser Pro 1 5 10 15 Ser Gly Gin Ser He He Arg Thr Gin Pro Gly Ala Gly Val His Pro 20 25 30 40 Lys Ala Asp Gly Ala Leu Lys Gly Glu Ala Glu Gin Ser Ala Gly His 35 40 45 Pro Ser Glu His Leu Phe He Cys Glu Glu Cys Gly Arg Cys Lys Cys 50 55 60 Val Pro Cys Thr Ala Ala Arg Pro Leu Pro Ser Cys Trp Leu Cys Asn 45 65 70 75 80 Gin Arg Cys Leu Cys Ser Ala Glu Ser Leu Leu Asp Tyr Gly Thr Cys 85 90 95 Leu Cys Cys Val 100 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 252 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (vi) ORIGINAL SOURCE: (C) ISOLATE: m-spryl (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 2...250 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: G GCC TCC TTG AAA GAG GAC CCC ACC CAG CAC AAG TTC ATC TGC GAA CAG 49 Ala Ser Leu Lys Glu Asp Pro Thr Gin His Lys Phe He Cys Glu Gin 1 5 10 15 TGT GGC AAG TGC AAA TGT GGA GAG TGT ACG GCC CCC CGG CGC ATG CCA 97 Cys Gly Lys Cys Lys Cys Gly Glu Cys Thr Ala Pro Arg Arg Met Pro 20 25 30 TCC TGT CTG GCC TGT GAT CGG CAG TGC CTC TGC TCC GCG GAG AGC ATG 145 Ser Cys Leu Ala Cys Asp Arg Gin Cys Leu Cys Ser Ala Glu Ser Met 35 40 45 GTG GAA TAC GGG ACC TGC ATG TGC CTG GTC AAG GGC ATT TTC TAC CAC 193 Val Glu Tyr Gly Thr Cys Met Cys Leu Val Lys Gly He Phe Tyr His 50 55 60 AGC TCC AAT GAT GCT GAT GGA GGT TCT TAC TCG GAT AAC CCA TGC TCC 241 Ser Ser Asn Asp Ala Asp Gly Gly Ser Tyr Ser Asp Asn Pro Cys Ser 65 70 75 80 TGT TCA CAG TC 252 Cys Ser Gin (2) INFORMATION FOR SEQ ID NO : 13 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 83 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (C) ISOLATE: m-spryl cysteine-rich region (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: Ala Ser Leu Lys Glu Asp Pro Thr Gin His Lys Phe He Cys Glu Gin 1 5 10 15 Cys Gly Lys Cys Lys Cys Gly Glu Cys Thr Ala Pro Arg Arg Met Pro 20 25 30 Ser Cys Leu Ala Cys Asp Arg Gin Cys Leu Cys Ser Ala Glu Ser Met 35 40 45 Val Glu Tyr Gly Thr Cys Met Cys Leu Val Lys Gly He Phe Tyr His 50 55 60 Ser Ser Asn Asp Ala Asp Gly Gly Ser Tyr Ser Asp Asn Pro Cys Ser 65 70 75 80 Cys Ser Gin (2) INFORMATION FOR SEQ ID NO : 14 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 504 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (vi) ORIGINAL SOURCE: (C) ISOLATE: m-spry2 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 14 : AATTTCAAAC GTTAATATAT TTTCTATTTT ATATTGAACA TAGCATCTGT AACCTCTCCT 60 TGGCAGCAAC CATCACATCC TCATAAAAGG GGCAAAATTT ATGATGCCTC TTAAAATAAA 120 TATTCTTTTT TTTTATAAAA TAATAAAACT TCAAATAAAT ATTCTTTACA CTAAACAATA 180 TGTTGAAAAA ATTAGAAAAT AAAGGTTGAA TTTTACTGTA ACTGTACAAT ATACATCAAG 240 TCCAAAGGGA AATCAGAGAC TTACAATAAA GGTTTCCTGT AAGGCAAAAT ACAATCTAAA 300 AACATACTGA TTGATTCACA TTCTTCCGAA TGTACAACAT ATTAGTATAA TATTTTGTGA 360 CTGTGCCATG AAGCATAGCA CAACTTGTTT TTTTTCACAG TTGCAAATAT TATCGTATAT 420 ACAAAAATAT AGCACATTAT CTCTGGAGAA AACAAGGAGG GGTCCGGGAG CCATTTGCTA 480 ATTTACACAT TTTGCATGGG CTAT 504 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 456 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTISENSE: NO (vi) ORIGINAL SOURCE: (C) ISOLATE: m-spry4 (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 3...353 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: GC AAC CAG GAG TGC CTG TGC TCG GCT CAG ACG CTG GTC AAC TAT GGC 47 Asn Gin Glu Cys Leu Cys Ser Ala Gin Thr Leu Val Asn Tyr Gly 1 5 10 15 ACA TGC ATG TGT CTG GTG CAA GGT ATC TTC TAT CAC TGT ACT AAT GAG 95 Thr Cys Met Cys Leu Val Gin Gly He Phe Tyr His Cys Thr Asn Glu 20 25 30 GAT GAT GAG GGC TCT TGC GCC GAC CAC CCC TGC TCC TGT TCC GGC TCC 143 Asp Asp Glu Gly Ser Cys Ala Asp His Pro Cys Ser Cys Ser Gly Ser 35 40 45 AAC TGC TGC GCC CGC TGG TCC TTC ATG GGC GCC CTC TCT GTG GTG CTG 191 Asn Cys Cys Ala Arg Trp Ser Phe Met Gly Ala Leu Ser Val Val Leu 50 55 60 CCC TGT CTG CTG TGC TAC CTG CCG GCC ACA GGC TGC GTC AAG CTG GCC 239 Pro Cys Leu Leu Cys Tyr Leu Pro Ala Thr Gly Cys Val Lys Leu Ala 65 70 75 CAG CGA GGC TAC GAC CGC CTG AGA CGC CCC GGT TGC CGC TGC AAG CAC 287 Gin Arg Gly Tyr Asp Arg Leu Arg Arg Pro Gly Cys Arg Cys Lys His 80 85 90 95 ACG AAC AGC GTC ATC TGC AAG GCA GCA AGT GGG GAC ACC AAG ACC AGC 335 Thr Asn Ser Val He Cys Lys Ala Ala Ser Gly Asp Thr Lys Thr Ser 100 105 110 AGG TCT GAC AAG CCT TTC TGACACTTTG GATGAAAAAA ACATGGTCCC TCCTGCCA 391 Arg Ser Asp Lys Pro Phe 115 GTCTCCTGAG ACTGACCTTG CTCATCTGTC CTCTCTAAAA CCCTAGATTG GGAAGAAACC 451 GGCAG 456 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 117 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (C) ISOLATE: m-spry4 cysteine-rich region (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Asn Gin Glu Cys Leu Cys Ser Ala Gin Thr Leu Val Asn Tyr Gly Thr 1 5 10 15 Cys Met Cys Leu Val Gin Gly He Phe Tyr His Cys Thr Asn Glu Asp 20 25 30 Asp Glu Gly Ser Cys Ala Asp His Pro Cys Ser Cys Ser Gly Ser Asn 35 40 45 Cys Cys Ala Arg Trp Ser Phe Met Gly Ala Leu Ser Val Val Leu Pro 50 55 60 Cys Leu Leu Cys Tyr Leu Pro Ala Thr Gly Cys Val Lys Leu Ala Gin 65 70 75 80 Arg Gly Tyr Asp Arg Leu Arg Arg Pro Gly Cys Arg Cys Lys His Thr 85 90 95 Asn Ser Val He Cys Lys Ala Ala Ser Gly Asp Thr Lys Thr Ser Arg 100 105 110 Ser Asp Lys Pro Phe 115 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spry2 highly conserved cysteine-rich region (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: Cys Glu Asp Cys Gly Lys Cys Lys Cys Lys Glu Cys Thr Tyr Pro Arg 1 5 10 15 Pro Leu Pro Ser Asp Trp He Cys Asp Lys Gin Cys Leu Cys Ser Ala 20 25 30 Gin Asn Val He Asp Tyr Gly Thr Cys Val Cys Cys Val 35 40 45 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spryl highly conserved cysteine-rich region (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Cys Glu Gin Cys Gly Lys Cys Lys Cys Gly Glu Cys Thr Ala Pro Arg 1 5 10 15 Thr Leu Pro Ser Cys Leu Ala Cys Asn Arg Gin Cys Leu Cys Ser Ala 20 25 30 Glu Ser Met Val Glu Tyr Gly Thr Cys Met Cys Leu Val 35 40 - 45 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (C) ISOLATE: h-spry3 highly conserved cysteine-rich region (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Cys Glu Glu Cys Gly Arg Cys Lys Cys Val Pro Cys Thr Ala Ala Arg 1 5 10 15 Pro Leu Pro Ser Cys Trp Leu Cys Asn Gin Arg Cys Leu Cys Ser Ala 20 25 30 Glu Ser Leu Leu Asp Tyr Gly Thr Cys Leu Cys Cys Val 35 40 45

Claims: IT IS CLAIMED: 1. An isolated recombinant sprouty polypeptide comprising a protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO: 8, or a peptide derived therefrom, and having at least 10 amino acids. 2. The sprouty protein of claim 1, whose cysteine-rich region has at least 50% sequence identity with SEQ ID NO: 17. 3. The sprouty protein of claim 1, which is a human sprouty 2 protein having a sequence substantially identical to SEQ ID NO: 8. 4. The sprouty protein of claim 1, which is a human sprouty 1 protein having a sequence substantially identical to SEQ ID NO:6. 5. The sprouty protein of claim 1, which is a human sprouty 3 protein having a sequence substantially identical to SEQ ID NO:ll. 6. The protein of claim 1, for use in treating a solid tumor in a patient, by administering to the patient an amount of the protein effective to inhibit tumor growth. 7. The protein of claim 6, which is selected from the group consisting of human sprouty 2 protein having a sequence substantially identical to SEQ ID NO: 8, human sprouty 1 protein having a sequence substantially identical to SEQ ID NO:6, and human sprouty 3 protein having a sequence substantially identical to SEQ ID NO: 11. 8. The protein of claim 6, which is encapsulated in liposomes having an average size less than about 150 nm, and a surface coating of polyethyleneglycol. 9. An isolated DNA fragment that encodes a sprouty polypeptide comprising (i) a protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID N0:8, or (ii) a peptide derived therefrom, and having at least 10 amino acids. 10. The DNA fragment of claim 9, that encodes a sprouty protein whose cysteine-rich 5 region has at least 50% sequence identity with SEQ ID NO: 17. 11. The DNA fragment of claim 9, which encodes a human sprouty 2 protein having a sequence substantially identical to SEQ ID NO: 8. 10 12. The DNA fragment of claim 11, whose coding sequence is substantially identical to SEQ ID. NO:7. 13. The DNA fragment of claim 9, which encodes a human sprouty 1 protein having a sequence substantially identical to SEQ ID NO:6. 15 14. The DNA fragment of claim 13, whose coding sequence is substantially identical to SEQ ID. NO:5. 15. The DNA fragment of claim 9, which encodes a human sprouty 3 protein having a 20 sequence substantially identical to SEQ ID NO: 11. 16. The DNA fragment of claim 15, whose coding sequence is substantially identical to SEQ ID. NO: 10. 25 17. A recombinant expression vector, comprising the DNA fragment that encodes a mammalian sprouty protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity with SEQ ID NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO:8, and 30 operably linked to said fragment, a regulatory sequence capable of promoting expression of the protein in a selected host. 18. The vector of claim 17, which is complexed with a polycation to form a condensed particle having a size less than about 150 nm, for use transfecting cells, to increase production of the sprouty protein from the cells. 19. The vector of claim 17, wherein said complex further includes a targeting moiety capable of binding specifically to tumor cell surfaces. 5 20. A mammalian cell transformed with the vector of claim 17. 21. A method of detecting a condition characterized by, or risk factor associated with, abnormal levels of active mammalian sprouty protein in a mammalian subject, comprising 10 obtaining genomic DNA or cDNA from the subject, and examining the DNA or cDNA for the presence or absence of mutations relative to the human sprouty genes selected from the group consisting of genes identified by SEQ ID NO: 5, SEQ ID NO:7, and SEQ ID NO: 11. 15 22. A method of detecting a condition characterized by, or risk factor associated with, abnormal levels of active mammalian sprouty protein in a mammalian subject, comprising obtaining fluid from a tissue or organ in the subject, reacting the fluid with an antibody against a human sprouty protein containing an amino acid sequence whose cysteine-rich region has at least 40% sequence identity with SEQ ID 0 NO: 17 in the human sprouty 2 protein whose full length sequence is identified by SEQ ID NO: 8, to form a protein-antibody complex, and identifying the presence of such complex.

Inventors: HACOHEN NIR, KRASNOW MARK A, HACOHEN, NIR, KRASNOW, MARK, A.
Applicants: UNIV LELAND STANFORD JUNIOR, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO
Application year: 1997
Main classification: C07K14
IPC codes: A61K38, A61K48, A61P35, C07K14, C12N5, C12N15, C12Q1, G01N33